Patent Application
20240139025
Described here are devices that, in some embodiments, are configured to engage with a syringe and to reduce a dead volume of the syringe and/or an air space or dead space around or adjacent to a distal end of the syringe.
The eye is a complex organ comprised of many parts that enable the process of sight. Vision quality depends on the condition of each individual part and the ability of these parts to work together. For example, vision may be affected by conditions that affect the lens (e.g., cataracts), retina (e.g., CMV retinitis), or the macula (e.g., macular degeneration). Topical and systemic drug formulations have been developed to treat these and other ocular conditions, but each has its drawbacks. For example, topical therapies that are applied on the surface of the eye typically possess short residence times due to tear flow that washes them out of the eye. Furthermore, delivery of drugs into the eye is limited due to the natural barrier presented by the cornea and sclera, and additional structures if the intended target resides within the posterior chamber. With respect to systemic treatments, high doses of drug are often required in order to obtain therapeutic levels within the eye, which increases the risk of adverse side-effects.
Alternatively, intravitreal injections have been performed to locally deliver pharmaceutical formulations into the eye. The use of intravitreal injections has become more common due to the increased availability of anti-vascular endothelial growth factor agents for the treatment of acute macular degeneration (AMD). Agents approved by the FDA for intravitreal injection to treat AMD include ranibizumab (Lucentis®: Genentech, South San Francisco, CA) and pegaptanib sodium (Macugen®: Eyetech Pharmaceuticals, New York, NY). In addition, intravitreal bevacizumab (Avastin®: Genentech, South San Francisco, CA) has been widely used in an off-label application to treat choroidal neovascularization. Increased interest in developing new drugs for delivery directly into the vitreous for the treatment of macular edema, retinal vein occlusion, and vitreous hemorrhage also exists.
Currently, commercially available intravitreal injection devices lack many features that are useful in exposing the site of injection, stabilizing the device against the sclera, and/or controlling the angle and depth of injection. Many of the devices described in the patent literature, e.g., WO 2008/084064 and U.S. 2007/0005016, are also part of multi-component systems that are generally time consuming to set up and use. The increased procedure time associated with these devices may in turn increase the risk of complications. Further, having to manipulate many components by itself may increase the risk of complications due to user error. A serious complication of intraocular injection is intraocular infection, termed endophthalmitis that occurs due to the introduction of pathogenic organisms such as bacteria from the ocular surface into the intraocular environment, or trauma to the ocular surface tissues such as corneal or conjunctiva! abrasion.
Accordingly, new devices for performing intravitreal injections would be desirable. Ergonomic devices that simplify the injection procedure and reduce the risk of complications would be useful. Devices that accurately and atraumatically inject drugs, e.g., liquid, semisolid, or suspension-based drugs, into the eye would also be useful.
Described here are devices, methods, and systems for delivering pharmaceutical formulations into the eye. The devices may be integrated. By “integrated” it is meant that various features that may be beneficial in delivering the pharmaceutical formulations into the eye, e.g., in a safe, sterile, and accurate manner, are combined into a single device. For example, features that may aid appropriate placement on the desired eye surface site, help position the device so that the intraocular space is accessed at the proper angle, help to keep the device tip stable without moving or sliding on the ocular surface once it has been positioned during the entire drug injection, adjust or control intraocular pressure, and/or help to minimize trauma, e.g., from the force of drug injection or contact or penetration of the eye wall itself, may be integrated into a single device. More specifically, the integrated devices may be used in minimizing trauma due to direct contact with the target tissue or indirectly through force transmission through another tissue or tissues such as the eye wall or vitreous gel, as well as minimizing trauma to the cornea, conjunctiva, episclera, sclera, and intraocular structures including, but not limited to, the retina, the choroid, the ciliary body, and the lens, as well as the blood vessels and nerves associated with these structures. Features that may be beneficial in reducing the risk of intraocular infectious inflammation such as endophthalmitis and those that may reduce pain may also be included. It should be understood that the pharmaceutical formulations may be delivered to any suitable target location within the eye, e.g., the anterior chamber or posterior chamber. Furthermore, the pharmaceutical formulations may include any suitable active agent and may take any suitable form. For example, the pharmaceutical formulations may be a solid, semi-solid, liquid, etc. The pharmaceutical formulations may also be adapted for any suitable type of release. For example, they may be adapted to release an active agent in an immediate release, controlled release, delayed release, sustained release, or bolus release fashion.
In general, the devices described here include a housing sized and shaped for manipulation with one hand. The housing typically has a proximal end and a distal end, and an ocular contact surface at the housing distal end. A conduit in its pre-deployed state will usually reside within the housing. The conduit will be at least partially within the housing in its deployed state. In some instances, the conduit is slidably attached to the housing. The conduit will generally have a proximal end, a distal end, and a lumen extending therethrough. An actuation mechanism may be contained within the housing that is operably connected to the conduit and a reservoir for holding an active agent. A trigger may also be coupled to the housing and configured to activate the actuation mechanism. In one variation, a trigger is located on the side of the device housing in proximity to the device tip at the ocular contact surface (the distance between the trigger and device tip ranging between 5 mm to 50 mm, between 10 mm to 25 mm, or between 15 mm to 20 mm), so that the trigger can be easily activated by a fingertip while the device is positioned over the desired ocular surface site with the fingers of the same hand. In another variation, a trigger is located on the side of the device housing at 90 degrees to a measuring component, so that when the device tip is placed on the eye surface perpendicular to the limbus, the trigger can be activated with the tip of the second or third finger of the same hand that positions the device on the ocular surface. In one variation, a measuring component is attached to the ocular contact surface. In some variations, a drug loading mechanism is also included.
The actuation mechanism may be manual, automated, or partially automated. In one variation, the actuation mechanism is a spring-loaded actuation mechanism. Here the mechanism may include either a single spring or two springs. In another variation, the actuation mechanism is a pneumatic actuation mechanism.
The application of pressure to the surface of the eye may be accomplished and further refined by including a resistance component, e.g., a dynamic resistance component to the injection device. The dynamic resistance component may include a slidable element coupled to the housing. In some variations, the slidable element comprises a dynamic sleeve configured to adjust the amount of pressure applied to the eye surface. In other variations, the dynamic resistance component is configured as an ocular wall tension control mechanism.
In one variation, the injection device includes a housing sized and shaped for manipulation with one hand, the housing having a proximal end and a distal end, a resistance band at least partially surrounding the housing having a thickness between about 0.01 mm to about 5 mm, a dynamic resistance component having proximal end and a distal end, an ocular contact surface at the housing or device distal end; a conduit at least partially within the housing, the conduit having a proximal end, a distal end, and a lumen extending therethrough, and an actuation mechanism coupled to the housing and operably connected to the conduit and a reservoir for holding an active agent.
In another variation, the injection device includes integrated components and includes a housing sized and shaped for manipulation with one hand, the housing having a proximal end and a distal end, and a sectoral measuring component coupled to a distal end of the housing or device. The sectoral measuring component may have a circumference or periphery, or have a central (core) member having a proximal end, a distal end, and a circumference, and comprising a plurality of radially extending members. The injection device may also include a conduit at least partially within the housing, the conduit having a proximal end, a distal end, and a lumen extending therethrough, an actuation mechanism coupled to the housing and operably connected to the conduit and a reservoir for holding an active agent, and a dynamic resistance component.
In yet a further variation, the injection device may include a housing sized and shaped for manipulation with one hand, the housing having a wall, a proximal end and a distal end, an ocular contact surface at the housing or device distal end, a conduit at least partially within the housing, the conduit having a proximal end, a distal end, and a lumen extending therethrough, an actuation mechanism coupled to the housing and operably connected to a reservoir for holding an agent, a dynamic resistance component, and a filter coupled to the device.
In some variations, the injector device for delivering a drug can be removably attached to a drug reservoir, and may include a needle assembly, the needle assembly comprising a drug conduit; a measuring component; and a priming-enabling component.
Described here are also systems for delivering compositions into the eye. The systems may include a housing sized and shaped for manipulation with one hand, the housing having a proximal end and a distal end; and an ocular contact surface at the housing distal end. The conduit may at least be partially disposed within the housing, and have a proximal end, a distal end, and a lumen extending therethrough. Typically a reservoir is disposed within the housing for holding the composition that comprises an active agent. Here the systems may also include a variable resistance component coupled to the housing distal end and an air removal mechanism, where the air removal mechanism is configured to remove air from the composition before the composition is delivered into the eye.
Alternatively, the systems for delivering a composition into the eye may include a syringe body having a proximal end and a distal end, and a reservoir for containing a composition therein, and an injector attachment removably coupled to the distal end of the syringe comprising a variable resistance component. The system may further include an air removal mechanism disposed within the injector attachment, where the air removal mechanism is configured to remove air from the composition before the composition is delivered into the eye.
The systems described herein may further comprise a terminal sterilization mechanism and/or a jet control mechanism in addition to an air removal mechanism. The air removal mechanism may comprise a hydrophobic filter material having a pore size. The pore size may range from about 0.05 μm to about 50 μm, from about 0.1 μm to about 10 μm, or from about 0.2 μm to about 5 μm. In some variations the air removal mechanism comprises a plurality of hydrophobic filters. The inclusion of an air removal mechanism may be particularly beneficial when a composition comprising ranibizumab or other viscous compositions are injected into the eye.
The drug delivery systems may specifically be provided with an air or gas-resistance component (e.g., a hydrophilic filter) and a vent (e.g., a hydrophobic filter). A hydrophilic filter membrane may increase the resistance to air or gas flow and prevent it from passing through a drug conduit while also diverting it through a hydrophobic filter vent and out of the device to facilitate air or gas removal from the drug composition. The vent and gas-resistance resistance components may be adjacent to each other. The vent and gas-resistance components may also be integrally formed with the drug conduit or needle hub, or provided as separate, attachable/detachable components (with the needle hub or any part of the injection device). The gas-resistance component may be at least partially air-impermeable under any condition, or at least partially air-impermeable under certain conditions, e.g., when wetted. The gas-resistance component may prevent air in the drug composition from entering a drug conduit. The vent may provide an anti-airlock mechanism, or a gas (air)-removal mechanism. For example, the vent may comprise an air-release valve or a hydrophobic membrane.
In some variations, the systems for delivering a pharmaceutical formulation into the eye include an injector device and a drug reservoir. Here the injector device can be removably attached to a drug reservoir, and may include a needle assembly, the needle assembly comprising a drug conduit; a measuring component; and a priming-enabling component. The pharmaceutical formulations may include an anti-VEGF agent selected from the group consisting of ranibizumab, bevacizumab, aflibercept, and modifications, derivatives, and analogs thereof, and combinations thereof, as the active agent. In one variation, the administration of ranibizumab or bevacizumab may be beneficial. In other variations, the pharmaceutical formulation may include aflibercept, ocriplasmin, a steroid, a placenta-derived growth factor, a platelet-derived growth factor, or combinations thereof, as the active agent. In further variations, the active agent may comprise an anti-complement agent, an anti-complement fraction agent, a complement-blocking agent, a complement-enhancing agent, a classic complement pathway inhibiting agent, an alternative complement inhibiting agent, a classic complement pathway potentiating agent, an alternative complement potentiating agent, or a combination thereof.
In use, the devices deliver drug into the intraocular space by positioning an ocular contact surface of the integrated device on the surface of an eye, where the device further comprises a reservoir for holding an active agent and an actuation mechanism, and applying pressure against the surface of the eye at a target injection site using the ocular contact surface, and then delivering an active agent from the reservoir into the eye by activating the actuation mechanism. The steps of positioning, applying, and delivering are completed with one hand. In some instances, a topical anesthetic is applied to the surface of the eye before placement of the device on the eye. An antiseptic may also be applied to the surface of the eye before placement of the device on the eye.
The application of pressure against the surface of the eye using the ocular contact surface may also generate an intraocular pressure ranging between 15 mm Hg to 120 mm Hg, between 20 mm Hg to 90 mm Hg, or between 25 mm Hg to 60 mm Hg. As further described below, the generation of intraocular pressure before deployment of the dispensing member (conduit) may reduce scleral pliability, which in turn may facilitate the penetration of the conduit through the sclera, decrease unpleasant sensation associated with the conduit penetration through the eye wall during an injection procedure and/or prevent backlash of the device.
The methods may also include placing an ocular contact surface of an injection device against the eye wall, generating variable resistance to conduit advancement as the conduit is deployed through the eye wall, removing air from the composition before the composition is delivered into the eye by passing the composition through an air removal mechanism, and injecting the composition into the eye. The force required to initiate movement against the generated resistance may be about 5 gm to about 100 gm of force or about 10 gm to about 30 gm of force. In some variations, it may take about 20 gm to about 25 gm of force to initiate movement of the resistance component.
In some instances, the method may include coupling an injector attachment to a syringe body, the injector attachment comprising a variable resistance component, an air removal mechanism, an ocular contact surface, and a needle, and the syringe body having a proximal end and a distal end, and a reservoir for containing a composition therein; placing the ocular contact surface of the injector attachment against the eye wall; generating variable resistance to needle advancement as the needle is deployed through the eye wall; removing air from the composition before the composition is delivered into the eye by passing the composition through the air removal mechanism; and injecting the composition into the eye.
The drug delivery devices, components thereof, and/or various active agents may be provided in systems or kits as separately packaged components. The systems or kits may include one or more injection devices and/or injector attachments, as well as one or more active agents. The devices may be preloaded or configured for manual drug loading. When a plurality of active agents is included, the same or different active agents may be used. The same or different doses of the active agent may be used as well. The systems or kits will generally include instructions for use. They may also include anesthetic agents and/or antiseptic agents.
Also disclosed herein are embodiments of an injection device, comprising one or more of: a barrel comprising an opening at a proximal end of the barrel, an opening at a distal end of the barrel, and a sidewall between the proximal end and the distal end, the barrel configured to house a volume of a therapeutic agent; and a plunger comprising an elongate body extending from a proximal end of the plunger to a distal end of the plunger, a first seal at the distal end of the plunger, and a second seal proximal to and spaced apart from the first seal.
Also disclosed herein are embodiments of an injection device comprising a barrel configured to house a volume of a therapeutic agent, the barrel comprising an opening at a proximal end of the barrel, an opening at a distal end of the barrel, and a sidewall between the proximal end and the distal end, and a plunger comprising a proximal section, a middle section, and a distal section, an elongate body extending from the proximal section of the plunger to the distal section of the plunger, a first seal at the distal section of the plunger, and a second seal at the middle section of the plunger. In any embodiments disclosed herein, the injection device can be configured such that, when the plunger is positioned at an extended position within the barrel, the first seal is positioned within a distal section of the barrel and the second seal is positioned within a middle section of the barrel. In any embodiments disclosed herein, the injection device can be configured such that, when the plunger is positioned at a retracted position within the barrel, the first seal is positioned within the middle section of the barrel and the second seal is positioned within a proximal section of the barrel. In any embodiments disclosed herein, the retracted position of the first seal is distal to the extended position of the second seal.
Also disclosed herein are embodiments of an injection device comprising a barrel comprising an opening at a proximal end of the barrel, an opening at a distal end of the barrel, and a sidewall between the proximal end and the distal end, the barrel configured to house a volume of a therapeutic agent and a plunger comprising: a proximal end, a distal end, and an elongate body, a seal, and a backstop component configured to limit the axial movement of the plunger relative to the barrel, wherein the barrel can include an engagement feature configured to engage the backstop component of the plunger.
Any embodiments of the injection methods, devices and systems disclosed herein can include, in additional embodiments, one or more of the following steps, features, components, and/or details in any combination with any of the other steps, features, components, and/or details of any other embodiments disclosed herein: wherein the elongate body, the first seal, and the second seal of the plunger are made from the same material; wherein the elongate body, the first seal, and the second seal of the plunger are monolithically formed; wherein the plunger, the first seal, and the second seal comprise polyethylene, a modified polyethylene, or a similar material; wherein the injection device comprises a conduit or connector coupled to the distal end of the barrel; wherein an outer diameter of the first seal is larger than an outer diameter of the second seal; wherein an outer diameter of the first seal is from 2% to 10% larger than an outer diameter of the second seal or from approximately 2% to approximately 10% larger than an outer diameter of the second seal; wherein an outer diameter of the first seal is from 5% to 10% larger than an outer diameter of the second seal or from approximately 5% to approximately 10% larger than an outer diameter of the second seal; wherein an outer diameter of the first seal is at least 5% larger or at least approximately 5% larger than an outer diameter of the second seal; wherein the first seal is radially larger than the second seal; and/or wherein an axial thickness of the first seal is larger than an axial thickness of the second seal.
Further, any embodiments of the injection methods, devices and/or systems disclosed herein can include, in additional embodiments, one or more of the following steps, features, components, and/or details in any combination with any of the other steps, features, components, and/or details of any other embodiments disclosed herein: wherein a distal end portion of the barrel comprises a variable inner diameter segment configured to at least inhibit the plunger from being proximally displaced by a force exerted on the plunger by an injection target; wherein the variable inner diameter segment comprises a distal portion having a first inner diameter, a proximal portion having a second inner diameter, and a transition zone between the distal portion and the proximal portion, wherein the first inner diameter is larger than the second inner diameter; wherein an outer diameter of the second seal is greater than the second inner diameter; wherein an outer diameter of the first seal is greater than the second inner diameter; wherein the first seal is configured to engage the distal portion of the variable inner diameter segment and the second seal is configured to engage the proximal portion of the variable inner diameter segment; wherein an inner diameter of the barrel proximal to the variable inner diameter segment is substantially constant; wherein a distal end portion of the barrel comprises a variable inner diameter segment comprising a first segment and a second segment distal to the first segment, the second segment comprising an inner diameter that is greater than an inner diameter of the first segment; wherein the inner diameter of the second segment is between 0.1 mm and 0.5 mm greater or is between about 0.1 mm and about 0.5 mm greater than the inner diameter of the first segment; wherein the inner diameter of the second segment is 0.3 mm greater or is about 0.3 mm greater than the inner diameter of the first segment; and/or wherein the second segment has an axial length of between about 0.05 mm and about 0.20 mm.
Further, any embodiments of the injection methods, devices and/or systems disclosed herein can include, in additional embodiments, one or more of the following steps, features, components, and/or details in any combination with any of the other steps, features, components, and/or details of any other embodiments disclosed herein: wherein the injection device comprises a transition zone between the first segment and the second segment; wherein the transition zone comprises an axial length that is less than, and within 0.05 mm or about 0.05 mm of the length of the second segment; wherein the transition zone comprises an axial length that is less than and within 0.3 mm or about 0.03 mm of the length of the second segment; wherein the variable inner diameter segment at the distal end of the barrel is less than 10% or about 10% of the total axial length of the barrel; wherein the injection device comprises a luer connector coupled to the distal end of the barrel; wherein the volume is between 0.25 ml or about 0.25 ml and 20 ml or about 20 ml; wherein the volume is 1 ml or about 1 ml.
In any embodiments disclosed herein, the injection device can include one or more of a barrel comprising an open proximal end, an open distal end, and a sidewall therebetween. In some embodiments the barrel can be configured to house a volume of therapeutic agent and a plunger comprising a proximal end, a distal end, and an elongate body, wherein the distal end of the barrel comprises a variable inner diameter segment. In any embodiments, the variable inner diameter segment can include a distal portion having a first diameter and a proximal portion having a second diameter, wherein the first diameter is larger than the second diameter, such that a break loose force is produced at the variable inner diameter segment. In any embodiments disclosed herein, wherein the break loose force exceeds a force exerted on the plunger by an injection target such that the plunger is prevented from being proximally displaced by the force exerted on the plunger by the injection target. In any embodiments disclosed herein, the break loose force can exceed a glide force by 0.1 N or about 0.1 N to 1 N or about 1 N, or wherein the break loose force exceeds a glide force by 1 N or about 1 N to 5 N or about 5 N, or wherein the break loose force exceeds a glide force by 5 N or about 5 N to 12 N or about 12 N.
Further, any embodiments of the injection methods, devices and/or systems disclosed herein can include, in additional embodiments, one or more of the following steps, features, components, and/or details in any combination with any of the other steps, features, components, and/or details of any other embodiments disclosed herein: wherein the injection device comprises a transition zone between the distal portion of the variable inner diameter segment and the proximal portion of the variable inner diameter segment; wherein the plunger comprises a seal configured to engage the variable inner diameter segment of the barrel when the distal end of the plunger is positioned at the distal end of the barrel; wherein the plunger and the seal are monolithic or monolithically formed; wherein the plunger and the seal comprise polyethylene, a modified polyethylene, or a similar material; wherein the plunger comprises a first seal and a second seal; wherein the first seal is configured to engage the distal portion of the variable inner diameter segment and the second seal is configured to engage the proximal portion of the variable inner diameter segment; wherein an outer diameter of the first seal is larger than an outer diameter of the second seal; and/or wherein an axial thickness of the first seal is larger than an axial thickness of the second seal.
Any embodiments of the injection methods, devices and/or systems disclosed herein can include, in additional embodiments, one or more of the following steps, features, components, and/or details in any combination with any of the other steps, features, components, and/or details of any other embodiments disclosed herein: wherein the plunger comprises the backstop component; wherein the injection device comprises a backstop component configured to limit a retraction of the plunger from the barrel such that the retracted position of the first seal is distal to the extended position of the second seal; and/or wherein the backstop component comprises an external clip.
Any embodiments of the injection methods, devices and/or systems disclosed herein can include, in additional embodiments, one or more of the following steps, features, components, and/or details in any combination with any of the other steps, features, components, and/or details of any other embodiments disclosed herein: wherein the engagement feature of the barrel comprises a ring; wherein the engagement feature is positioned at a proximal section of the barrel; wherein the plunger, the seal, and the backstop component are monolithic or monolithically formed; wherein the seal is positioned near the distal end of the plunger; wherein the seal and the backstop component are positioned along the plunger such that the seal is prevented from being retracted proximally past a midpoint of the barrel; and/or wherein the seal and the backstop component are positioned along the plunger such that the seal remains in a distal section of the barrel when the plunger is in a retracted position relative to the barrel.
Also disclosed herein are embodiments of a method of using an injection device comprising providing an injection device comprising a barrel and a plunger, positioning the injection device in an at rest position, wherein, in the at rest position, a distal end of the plunger is proximal to a distal end of the barrel, extending the plunger within the barrel to an extended position, wherein, in the extended position, the distal end of the plunger is near the distal end of the barrel, retracting the plunger within the barrel to a loaded position, wherein the loaded position of the plunger is proximal to the extended position of the plunger and distal to the at rest position of the plunger. In any embodiments disclosed herein, in the at rest position, the plunger is retracted 1/10 or about 1/10 to 9/10 or about 9/10 of the length of the barrel, or is retracted 3/10 or about 3/10 to 5/10 or about 5/10 of the length of the barrel. In any embodiments disclosed herein, the injection device or the method of use of the injection device can be configured such that retracting the plunger within the barrel to a loaded position causes a volume of therapeutic agent to be introduced into the barrel. In any embodiments disclosed herein, the method of using an injection device further includes extending the plunger from the loaded position to deliver the volume of therapeutic agent.
Also disclosed herein are embodiments of a cap or other device having a luer taper for a syringe. In some embodiments, the cap can include a body portion having a first end and a second end, an end wall, a hub at the first end of the body portion, the hub extending axially away from the end wall and having a first interior surface having a female luer taper configured to sealingly mate with a male luer taper of the syringe, and a volume displacing protrusion extending in a longitudinal axial direction away from the end wall. In some embodiments, the volume displacing protrusion can be configured to contact a distal end of the syringe before the distal end of the syringe forms an air-tight seal with the female luer taper of the hub.
Any embodiments of the cap or other device having a luer taper disclosed herein can include, in additional embodiments, one or more of the following features, components, and/or other details in any combination with any of the other features, components, and/or details of any other embodiments disclosed herein: wherein the volume displacing protrusion has a spherical surface; wherein the volume displacing protrusion can be configured to form an air-tight seal against the distal end of the syringe before the distal end of the syringe forms an air-tight seal with female luer taper of the hub; wherein the volume displacing protrusion can be configured to form an air-tight seal against the distal end of the syringe without inhibiting or preventing a plunger of the syringe from advancing to the distal end of the syringe; wherein the end wall is flexible; wherein the volume displacing protrusion is flexible; including a recess formed in the second end of the body portion of the cap; including a depression formed in the end wall of the cap, and/or wherein the volume displacing protrusion can be formed in a first side of the end wall and the depression can be formed in a second side of the end wall that is opposite to first side of the end wall, the depression being configured to increase a flexibility of the end wall. Also disclosed herein are kits including the cap of any embodiments disclosed herein or including any other device having a luer taper and a syringe.
Also disclosed herein are embodiments of a cap for a syringe. In some embodiments, the cap can have a body portion having a first end and a second end, a hub at the first end of the body portion, the hub having a first interior surface having a female luer taper configured to sealingly mate with a male luer taper of the syringe, and a flexible element formed separate from the body portion and coupled with the body portion, the flexible element having a first main surface and a volume displacing protrusion extending in a longitudinal axial direction away from the first main surface. In some embodiments, the volume displacing protrusion can be configured to contact a distal end of the syringe before the distal end of the syringe forms an air-tight seal with the female luer taper of the hub. The volume displacing protrusion can have a spherical surface. The volume displacing protrusion can be configured to form an air-tight seal against the distal end of the syringe before the distal end of the syringe forms an air-tight seal with female luer taper of the hub. The volume displacing protrusion can be configured to form an air-tight seal against the distal end of the syringe without inhibiting or preventing a plunger of the syringe from advancing to the distal end of the syringe. The volume displacing protrusion can be flexible and configured to move or compress upon contact with the distal end of the syringe.
Also disclosed herein are kits including the cap of any embodiments disclosed herein or including any other device having a luer taper and a syringe.
Also disclosed herein are embodiments of a method of reducing a dead space within a distal end of a syringe. In some embodiments, the method can include advancing a distal tip of a syringe into a female hub of a syringe cap, the female hub having a female luer taper configured to sealingly mate with a male luer taper of the syringe, and preventing air from entering the distal tip of the syringe when the distal tip of the syringe can be advanced into the female hub of the syringe cap by sealing a distal end of the distal tip of the syringe before the distal end of the syringe forms an air-tight seal with the female luer taper of the hub. In some embodiments, the method can include preventing air from entering the distal tip of the syringe when the distal tip of the syringe can be advanced into the female hub of the syringe cap by sealing the distal end of the distal tip of the syringe with a flexible protrusion of the syringe cap before the distal end of the syringe forms an air-tight seal with the female luer taper of the hub. In some embodiments, the flexible protrusion can have a spherical surface configured to engage the distal end of the distal tip of the syringe. In some embodiments, the flexible protrusion can be configured to form an air-tight seal against the distal end of the syringe without inhibiting or preventing a plunger of the syringe from advancing to the distal end of the syringe. In some embodiments, the flexible protrusion can be flexible and configured to move or compress upon contact with the distal end of the syringe.
Also disclosed herein are embodiments of an injection system. In some embodiments, the injection system can have a syringe including a barrel having an internal cavity and an elongate plunger configured for sealed longitudinal movement within the cavity, the syringe having a distal end including a male luer taper, a hub including a distal portion and a proximal portion, the proximal portion including a first interior surface including a female luer taper configured to sealingly mate with the male luer taper of the syringe, an elongate tube having a lumen and extending from the distal end of the hub, and a proximally-extending projection within the proximal portion of the hub along a distal portion of the female luer taper, the projection having a central orifice, a distal end, a proximal end, a maximum diameter, and a minimum diameter, the orifice configured to communicate with the lumen of the elongate tube, wherein the minimum diameter can be at the proximal end of the projection and wherein the maximum diameter can be at the distal end of the projection, the projection further including a frustoconical outer surface extending between the proximal end and the distal end.
Any embodiments of the injection system disclosed herein can include, in additional embodiments, one or more of the following features, components, and/or other details in any combination with any of the other features, components, and/or details of any other embodiments disclosed herein: wherein the projection comprises a volume displacing protrusion; wherein the projection comprises a planar surface at the proximal end of the volume displacing protrusion; wherein a length of the projection in a lengthwise axial direction from the proximal end of the projection to the distal end of the projection can be greater than a wall thickness of the projection at any point along the length of the projection; wherein a length of the projection in a lengthwise axial direction from the proximal end of the projection to the distal end of the projection can be greater than a distance from an outside surface of the projection to a surface of the female leur taper at any point along the female luer taper; wherein the injection system can be configured to deliver one or more therapeutic agents selected from the group consisting of ranibizumab, bevacizumab, aflibercept, Fovista, ocriplasmin, and modifications, derivatives, and analogs thereof, and combinations thereof; and/or wherein the injection system can be configured to deliver one or more therapeutic agents selected from the group consisting of: an anti-VEGF agent, an anti-PDGF agent, an anti-PDGFR-β agent, an anti-complement factor agent, a steroid, a placenta-derived growth factor, and combinations thereof.
Also disclosed herein are embodiments of an injector device for drug delivery. In some embodiments, the injector device for drug delivery can have a needle hub including an input port on a proximal end of the needle hub, wherein the input port can be configured to be coupled with a luer connector at a distal end of a drug reservoir, and wherein the input port comprises a luer connector including a female tapered surface and an end wall at a distal end of the female tapered surface, a fluid passageway extending axially through the needle hub, a volume displacing protrusion extending in a proximal direction away from the end wall of the input port, the volume displacing protrusion having an opening therethrough that can be in fluid communication with and axially aligned with the fluid passageway extending axially through the needle hub, a space between at least a portion of the volume displacing protrusion and a distal end portion of the female tapered surface, and a needle having a proximal portion, a distal portion, an exit port on the distal portion, and a lumen extending therethrough.
Any embodiments of the injector device disclosed herein can include, in additional embodiments, one or more of the following features, components, and/or other details in any combination with any of the other features, components, and/or details of any other embodiments disclosed herein: wherein the lumen of the needle can be in fluid communication with the fluid passageway extending through the needle hub; wherein the proximal portion of the needle can be housed within the needle hub and the distal portion of the needle extends distally beyond the needle hub; wherein the space between the at least portion of the volume displacing protrusion and the distal end portion of the female tapered surface comprises an annular shape; wherein the space entirely surrounds a radially outer surface of the volume displacing protrusion; wherein a radially outer surface of the volume displacing protrusion comprises a truncated conical shape; wherein the volume displacing protrusion can be concentric with the input port; wherein the volume displacing protrusion and the needle hub are monolithic; wherein a wall of the volume displacing protrusion and a wall of the needle hub at the input port are substantially the same thickness; wherein a length of the volume displacing protrusion in a lengthwise axial direction from the end wall of the input port to a proximal end of the volume displacing protrusion can be less than one-third of a length of the female tapered surface in a lengthwise axial direction of the needle hub; wherein a dead volume can be formed when a male tapered luer connector can be inserted into the input port, the dead volume positioned between a distal end of the male tapered luer connector and the end wall of the input port, and the volume displacing protrusion reduces the dead volume; wherein the drug reservoir comprises one or more therapeutic agents configured for intravitreal injection; wherein the needle does not extend past a proximal end of the volume displacing protrusion; and/or wherein the drug reservoir comprises a syringe.
Disclosed herein are additional embodiments of an injector device for drug delivery. In some embodiments, the injector device for drug delivery can have a needle hub including an input port on a proximal end of the needle hub, wherein the input port can be configured to be removably coupled with a luer connector at a distal end of a syringe, and wherein the input port comprises a luer connector including a female tapered surface and an end wall at a distal end of the female tapered surface, a fluid passageway extending axially through the needle hub, a volume displacing protrusion extending in a proximal direction away from the end wall of the input port, the volume displacing protrusion having an opening therein that can be in fluid communication with and axially aligned with the fluid passageway extending axially through the needle hub, and a space between at least a portion of the volume displacing protrusion and a distal end portion of the female tapered surface.
In some embodiments, the injector device can further include a needle having a proximal portion, a distal portion, an exit port on the distal portion, and a lumen extending therethrough, wherein the lumen of the needle can be in fluid communication with the fluid passageway extending through the needle hub. In some embodiments, the proximal portion of the needle can be housed within the needle hub and the distal portion of the needle extends distally beyond the needle hub. In some embodiments, the space can have an annular shape. In some embodiments, the volume displacing protrusion can reduce the dead volume of the injector device. In some embodiments, the volume displacing protrusion and the needle hub can be monolithic.
Also disclosed herein are embodiments of a system for providing liquid access within an internal portion of a patient. In some embodiments, the system can include a syringe including a barrel having an internal cavity and an elongate plunger configured for sealed longitudinal movement within the cavity, the syringe having a distal end including a male luer taper, a hub including a distal portion and a proximal portion, the proximal portion including a first interior surface including a female luer taper configured to sealingly mate with the male luer taper, an elongate tube having a lumen and extending from the distal end of the hub, and a proximally-extending projection within the proximal portion of the hub along a distal portion of the female luer taper, the projection having a central orifice, a distal end, a proximal end, a maximum diameter, and a minimum diameter, the orifice configured to communicate with the lumen of the elongate tube, wherein the minimum diameter can be at the proximal end of the projection and wherein the maximum diameter can be at the distal end of the projection, the projection further including a frustoconical outer surface extending between the proximal end and the distal end.
FIGS. 3A1-3A3 and FIGS. 3B1-3B3 show side views of other exemplary ocular contact surfaces.
FIGS. 5A1-5A2 and FIGS. 5B1-5B2 depict side and perspective views of exemplary flat and convex ocular contact surfaces.
FIGS. 6A1-6A2 and FIGS. 6B1-6B2 show side and front views of exemplary soft or semi-solid ocular contact surfaces.
FIGS. 7A1-7A2, FIGS. 7B1-7B2, FIGS. 7C1-7C2, and
FIGS. 15A1-15A2 show side views of exemplary bevel angles.
Described here are hand-held devices, methods, and systems for delivering, e.g., by injection, pharmaceutical formulations into the eye. The devices may integrate (combine) various features that may be beneficial in delivering the pharmaceutical formulations into the eye, e.g., in a safe, sterile, and accurate manner, into a single device. That is, the devices may have a modular design. As used herein, the term “modular” refers to a device formed from a combination of various components that are capable of being attached to, and detached from, the device housing. For example, e.g., various resistance components, filters (e.g., a hydrophilic and/or hydrophobic filter combination), ocular measuring components, etc., may be configured as attachable/detachable components that can be combined with a syringe housing. Thus, features that may aid appropriate placement on the eye, help positioning so that the intraocular space is accessed at the proper angle and/or depth, adjust or control ocular wall tension, and/or help to minimize trauma to the sclera and intraocular structures, e.g., from the force of injection or penetration of the sclera itself, may be integrated into a single device. The devices, in whole or in part, may be configured to be disposable. The devices may also be configured to remove air, infectious agents, and/or particulate matter from formulations or compositions prior to their injection into the eye. For example, it may be advantageous to remove air from compositions comprising ranibizumab or other viscous compositions prior to injection of these compositions into the eye. This is so that the risk of the patient developing visual disturbances such as floaters can be eliminated or minimized.
In general, the integrated or modular devices described here include a housing sized and shaped for manipulation with one hand. The housing typically has a proximal end and a distal end, and an ocular contact surface at the housing distal end. A conduit tin its pre-deployed state may reside within the housing. The conduit will be at least partially within the housing in its deployed state. In some variations, the conduit is slidably attached to the housing. Additionally, the conduit will generally have a proximal end, a distal end, and a lumen extending therethrough. An actuation mechanism may be contained within the housing that is operably connected to the conduit and a reservoir for holding an active agent.
The devices or portions thereof may be formed from any suitable biocompatible material or combination of biocompatible materials. For example, one or more biocompatible polymers may be used to make, e.g., the device housing, ocular contact surface, measuring component, needle hub, slidable shield, safety clip, plunger, plunger seal, side plunger trigger-actuator, etc. Exemplary biocompatible materials include without limitation, methylmethacrylate (MMA), polymethylmethacrylate (PMMA), polyethylmethacrylate (PEM), and other acrylic-based polymers; polyolefins such as polypropylene and polyethylene; vinyl acetates; polyvinylchlorides; polyurethanes; polyvinylpyrollidones; 2-pyrrolidones; polyacrylonitrile butadiene; polycarbonates (e.g., polished polycarbonate and glass filled polycarbonate); polyamides; fluoropolymers such as polytetrafluoroethylene (e.g., TEFLON™ polymer); polystyrenes; styrene acrylonitriles; cellulose acetate; acrylonitrile butadiene styrene; polymethylpentene; polysulfones; polyesters; polyimides; natural rubber; polyisobutylene rubber; polymethylstyrene; silicone; thermoplastic elastomers such as Medalist® TPE (e.g., TPE MD-100 (5 durometer Shore A), TPE MD-105 (18 durometer Shore A), TPE MD-145 (50A durometer) and TPE MD-555 (55A durometer), and other thermoplastic elastomers having a durometer between about 2A and 70A, between about 40A and 70A, or between about 5A and 60A); and copolymers and blends thereof.
In some variations, the device or a portion of the device such as the drug reservoir, plunger, housing, ocular contact surface, or measuring component, is made of a material that includes a cyclic olefin series resin. Exemplary cyclic olefin resins include without limitation, commercially available products such as Zeonex® cyclo olefin polymer (ZEON Corporation, Tokyo, Japan) or Crystal Zenith® olefinic polymer (Daikyo Seiko, Ltd., Tokyo, Japan) and APEL™ cyclo olefin copolymer (COC) (Mitsui Chemicals, Inc., Tokyo, Japan), a cyclic olefin ethylene copolymer, a polyethylene terephthalate series resin, a polystyrene resin, a polybutylene terephthalate resin, and combinations thereof. In one variation, it may be beneficial to use a cyclic olefin series resin and a cyclic olefin ethylene copolymer that have high transparency, high heat resistance, and minimal to no chemical interaction with a pharmacological product such as a protein, a protein fragment, a polypeptide, or a chimeric molecule including an antibody, a receptor or a binding protein.
The cyclic olefin polymers or the hydrogenation products thereof can be ring-opened homopolymers of cyclic olefin monomers, ring-opened copolymers of cyclic olefin monomers and other monomers, addition homopolymers of cyclic olefin monomers, addition copolymers of cyclic olefin monomers and other monomers, and hydrogenation products of such homopolymers or copolymers. The above cyclic olefin monomers may include monocyclic olefin monomers, and polycyclic olefin monomers including bicyclic and higher cyclic compounds. Examples of the monocyclic olefin monomers suitable for the production of the homopolymers or copolymers of the cyclic olefin monomers are monocyclic olefin monomers such as cyclopentene, cyclopentadiene, cyclohexene, methylcyclohexene and cyclooctene; lower-alkyl derivatives thereof containing, as substituent groups, 1 to 3 lower alkyl groups such as methyl and/or ethyl groups; and acrylate derivatives thereof.
Examples of the polycyclic olefin monomers are dicyclopentadiene, 2,3-dihydrocyclopentadiene, bicyclo[2,2,1]-hepto-2-ene and derivatives thereof, tricyclo[4,3,0,12,5]-3-decene and derivatives thereof, tricyclo[4,4,0,12,5]-3-undecene and derivatives thereof, tetracyclo[4,4,0,12,5,07,10]-3-dodecene and derivatives thereof, pentacyclo[6,5,1,13,6,02,7,09,13 4-pentadecene and derivatives thereof, pentacyclo[7,4,0,12,5,008,1319,12]-3-pentadecene and derivatives thereof, and hexacyclo[6,6, 1,13,6,110,1302,709,14]-4-heptadecene and derivatives thereof. Examples of bicyclo[2,2,1]-hepto-2-ene derivatives include 5-methyl-bicyclo[2,2,1]-hepto-2-ene, 5-methoxy-bicyclo[2,2,1]-hepto-2-ene, 5-ethylidene-bicyclo[2,2,1]-hepto-2-ene, 5-phenyl-bicyclo[2,2,1]-hepto-2-ene, and 6-methoxycarbonyl-bicyclo[2,2,1-]-hepto-2-ene. Examples of tricyclo[4,3,0,12,5]-3-decene derivatives include 2-methyl-tricyclo[4,3,0,12,5]-3-decene and 5-methyl-tricyclo[4,3,0,12,5]-3-decene. Examples of tetracyclo[4,4,0,12,5]-3-undecene derivatives include 10-methyl-tetracyclo[4,4,0,12,5]-3-undecene, and examples of tricyclo[4,3,0,12,5]-3-decene derivatives include 5-methyl-tricyclo[4,3,0,12,5]-3-decene.
Examples of tetracyclo[4,4,0,12′5,07′10]-3-dodecene derivatives include 8-ethylidene-tetracyclo-[4,4,0,12,5,07,10]-3-dodecene, 8-methyl-tetracyclo-[4,4,0,12,5,07,10]-3-dodecene, 9-methyl-8-methoxy-carbonyl-tetracyclo[4,4,0,12′5,07′10]-3-dodecene, 5,10-dimethyl-tetracyclo[4,4,0,12,5,07,10]-3-dodecene. Examples of hexacyclo[6,6,1,13,6,110,13,02,7, 09,14]-4-heptadecene derivatives include 12-methyl-hexacyclo[6,6,1,13,6,110,13,02,7,09,14]-4-heptadecene and 1,6-dimethyl-hexacyclo[6,6,1,13,6,110,13,02,7,09,14]-4-heptadecene. One example of the cyclic olefin polymer is an addition homopolymer of at least one cyclic olefin monomer or an addition copolymer of at least one cyclic olefin monomer and at least one other olefin monomer (for example, ethylene, propylene, 4-methylpentene-1, cyclopentene, cyclooctene, butadiene, isoprene, styrene, or the like). This homopolymer or copolymer can be obtained by polymerizing the above monomer or monomers, for example, while using as a catalyst a known catalyst which is soluble in a hydrocarbon solvent and is composed of a vanadium compound or the like and an organoaluminum compound or the like (Japanese Patent Application Laid-Open (Kokai) No. HEI 6-157672, Japanese Patent Application Laid-Open (Kokai) No. HEI 5-43663).
Another example of the cyclic olefin polymer is a ring-opened homopolymer of the above monomer or a ring-opened copolymer of the above monomers. It can be obtained by homopolymerizing the above monomer or copolymerizing the above monomers, for example, while using as a catalyst a known catalyst such as (1) a catalyst composed of a halide or the nitrate of a platinum group metal such as ruthenium, rhodium, palladium, osmium or platinum and a reducing agent or (2) a catalyst composed of a compound of a transition metal such as titanium, molybdenum or tungsten and an organometal compound of a metal in one of Groups I to IV of the periodic table such as an organoaluminum compound or organotin compound (Japanese Patent Application Laid-Open (Kokai) No. HEI 6-157672, Japanese Patent Application Laid-Open (Kokai) No. HEI 5-43663).
The homopolymer or copolymer may contain unsaturated bonds. The homopolymer or copolymer may be hydrogenated using a known hydrogenation catalyst. Examples of the hydrogenation catalyst include (1) Ziegler-type homogeneous catalysts which are each composed of an organic acid salt of titanium, cobalt, nickel or the like and an organometal compound of lithium, aluminum or the like, (2) supported catalysts which are each composed of a carrier such as carbon or alumina and a platinum metal such as palladium or ruthenium supported on the carrier, and (3) catalysts which are each composed of a complex of one of the above-described platinum group metal (Japanese Patent Application Laid-Open (Kokai) No. HEI 6-157672).
In variations where the injection device includes a plunger, the plunger seal (plunger tip) may be made from a thermoplastic elastomer as previously described and coated with a silicone fluid such as a Dow Corning® 360 Medical Fluid, e.g., polydimethylsiloxane. Some variations of the plunger seal may be coated with a fluoropolymer instead of a silicone polymer. Exemplary fluoropolymer coatings may comprise polytetrafluoroethylene, fluorolene, fluoroglide, and combinations thereof. Other silicone-free coatings may also be used. When the plunger seal is uncoated, it may be made from polypropylene, polyethylene, or a cyclic olefin resin, or any modifications thereof. In other variations, the inner surface of the barrel is coated. The coatings here may be the same as the ones mentioned for the plunger seal. It may be useful to include a coating on the plunger seal, inner surface of the barrel, or both, because it may impart a predictable and constant plunger release (from a resting position) and travel/glide force (force required to advance the plunger through the barrel). Employment of a coating may result in a zero or near-zero break force (force required to start advancement of the plunger from a resting position). For example, when a coating is used, the break force may be equal to the travel force, or may be up to about 10 gm more than the travel force. Having a break force of zero, near-zero, or any one of the values mentioned above, may prevent an initial burst of fluid being injected into the eye that could potentially cause fluid waves and injure intraocular structures such as the retina. The coatings may help to prevent high, variable, and/or unpredictable initial plunger resistance, especially after prolonged storage.
In some variations, the device or a portion of the device such as the drug reservoir is made of a material that comprises polypropylene, polyethylene, or a rubber. Examples of suitable rubber materials include butyl rubbers such as butyl rubber, chlorinated butyl rubber, brominated butyl rubber, and divinylbenzene-copolymerized butyl rubber; conjugated diene rubbers such as polyisoprene rubber (high to low cis-1,4 bond), polybutadiene rubber (high to low cis-1,4 bond), and styrene-butadiene copolymer rubber; and ethylene-propylene-diene terpolymer rubber (EPDM). Crosslinkable rubber materials may also be used, and may be made by kneading the above-described rubber materials together with additives such as a crosslinking agent, a filler and/or reinforcement, a colorant, or an age resister.
In some variations, the biocompatible material is a biodegradable polymer. Non-limiting examples of suitable biodegradable polymers include cellulose and ester, polyacrylates (L-tyrosine-derived or free acid), poly(β-hydroxyesters), polyamides, poly(amino acid), polyalkanotes, polyalkylene alkylates, polyalkylene oxylates, polyalkylene succinates, polyanhydrides, polyanhydride esters, polyaspartimic acid, polylactic acid, polybutylene digloclate, poly(caprolactone), poly(caprolactone)/poly(ethylene glycol) copolymers, polycarbone, L-tyrosin-derived polycarbonates, polycyanoacrylates, polydihydropyrans, poly(dioxanone), poly-p-dioxanone, poly(s-caprolactone-dimethyltrimethylene carbonate), poly(esteramide), polyesters, aliphatic polyesters, poly(etherester), polyethylene glycol/poly(orthoester) copolymers, poly(glutarunic acid), poly(glycolic acid), poly(glycolide), poly(glycolide)/poly(ethylene glycol) copolymers, poly(lactide), poly(lactide-co-caprolactone), poly(DL-lactide-co-glycolide), poly(lactide-co-glycolide)/poly(ethylene glycol) copolymers, poly(lactide)poly(ethylene glycol) copolymers, polyphosphazenes, polyphosphesters, polyphophoester urethanes, poly(propylene fumarate-co-ethylene glycol), poly(trimethylene carbone), polytyrosine carbonate, polyurethane, terpolymer (copolymers of glycolide lactide or dimethyltrimethylene carbonate), and combinations, mixtures or copolymers thereof.
Additives may be added to polymers and polymer blends to adjust their properties as desired. For example, a biocompatible plasticizer may be added to a polymer formulation used in at least a portion of a device to increase its flexibility and/or mechanical strength, or to provide color contrast with respect to the surface of the eye. In other instances, a biocompatible filler such as a particulate filler, fiber and/or mesh may be added to impart mechanical strength and or rigidity to a portion of a device.
The devices described here can be manufactured, at least in part, by injection or compression molding the above-described materials.
In some instances, it may be beneficial to include a removably attached or integrated viewing and/or magnifying element on the device. For example, a magnifying glass and/or illumination source such as a LED light may be removably attached to the device to facilitate the visualization of the tip of the device and the injection site. The improved visualization may help to more precisely and safely position the device at a target location, e.g., about 3.5 mm to 4 mm posterior to the corneo-scleral limbus, so that complications of intraocular injection such as retinal detachment, ciliary body bleeding, or trauma to the intraocular lens can be potentially avoided. The magnifying glass may be made from any suitable material, e.g., it may be made from any suitable non-resorbable (biodegradable) material previously described, but will typically be light-weight so that it does not affect the balance of the injection device. The magnifying glass and/or illumination source, e.g., the LED, may be disposable.
The housing of the device generally contains the drug reservoir and actuation mechanism. In its first, non-deployed state (pre-deployed state), the conduit may reside within the housing. The housing may be of any suitable shape, so long as it allows grasping and manipulation of the housing with one hand. For example, the housing may be tubular or cylindrical, rectangular, square, circular, or ovoid in shape. In some variations, the housing is tubular or cylindrical, similar to the barrel of a syringe. In this instance, the housing has a length between about 1 cm and about 15 cm, between about 2.5 cm and about 10 cm, or about 4 cm and about 7.5 cm. For example, the housing may have a length of about 1 cm, about 2 cm, about 3 cm, about 4 cm, about 5 cm, about 6 cm, about 7 cm, about 8 cm, about 9 cm, about 10 cm, about 11 cm, about 12 cm, about 13 cm, about 14 cm, or about 15 cm. The surface of the housing may also be texturized, roughened, or otherwise modified in certain areas, e.g., with protrusions, ridges, etc., to aid the grip and or manipulation of the housing by the user. Grips may be associated with any one of the actuation mechanisms further described below. The grips are generally configured to help the operator maintain a steady grip on the device using, e.g., two, three or four fingers. The plunger actuation lever may be located on the device housing in the close proximity of the grip, for example, integrated with the grip, or between about 1.0 mm and 10 mm of the grip, so that the operator is able to easily use the fingers holding the device to actuate, e.g., slide, the actuation lever while maintaining a steady grip and without compromising the hold/control of the device. The distance that the actuation lever may travel may be between about 2.0 mm and about 8.0 mm, or between about 1.0 mm and about 15 mm). Maintaining a steady grip while actuating the drug injection mechanism is useful because it helps to localize the injection site on the eye surface with about a 0.5 mm precision accuracy.
In some variations, the housing comprises a syringe barrel having a distal end that includes a luer. The luer may be of any suitable type, e.g., slip-tip, luer-lock, or luer-snap type. When the luer is of the luer lock type, it may interface with a drug conduit by twisting the drug conduit on/off. When the luer is of the luer-snap type, it may comprise a raised edge on the outside surface of the luer tip that may interlock with a raised ridge located on the inside surface of the hub of a drug conduit to form a male-female type of connection. The luer-snap connection may enhance the connection strength between the housing (having a reservoir disposed within) and a drug conduit as compared to the slip-tip type of connection, but without the rigid lock that is achieved with a luer-lock type of connection.
Some variations of the luer-snap connector may provide tactile feedback to ensure that the drug conduit has been appropriately positioned and stably interfaced with the housing (e.g., that the hub of the drug conduit has been placed far enough onto the luer to prevent its accidental detachment during the drug injection procedure.
The luer-snap connector may further comprise a self-positioning mechanism to ensure the hub of the drug conduit has been stably positioned in the right location on the luer. The self-positioning mechanism may be a combination of interlocking raised ridges, where one ridge is located on the external surface of the luer and the other ridge is located on the internal surface of the drug conduit hub, but at least one of the ridges has a shallow leading slope and a steep trailing slope that may allow the drug conduit to self-position and snap into place once the ridges have been advanced past each other.
The housing may be made from any suitable material. For example, and as previously stated, the components of the device may be made from any suitable biocompatible material or combination of biocompatible materials. Materials that may be beneficial in making the housing include, without limitation, a cyclic olefin series resin, a cyclic olefin ethylene copolymer, a polyethylene terephthalate series resin, a polystyrene resin, and a polyethylene terephthalate resin. In one variation, it may be beneficial to use a cyclic olefin series resin and a cyclic olefin ethylene copolymer that have a high transparency, a high heat resistance, and minimal to no chemical interaction with a pharmacological product such as a protein, a protein fragment, a polypeptide, or a chimeric molecule including an antibody, a receptor or a binding protein. Additional materials that may be beneficial in making the housing include, without limitation, fluoropolymers; thermoplastics such as polyetheretherketone, polyethylene, polyethylene terephthalate, polyurethane, nylon, and the like; and silicone. In some variations, the housing may be made from a transparent material to aid confirmation of conduit deployment and/or drug delivery. Materials with suitable transparency are typically polymers such as acrylic copolymers, acrylonitrile butadiene styrene (ABS), polycarbonate, polystyrene, polyvinyl chloride (PVC), polyethylene terephthalate glycol (PETO), and styrene acrylonitrile (SAN). Acrylic copolymers that may be useful include, but are not limited to, polymethyl methacrylate (PMMA) copolymer and styrene methyl methacrylate (SMMA) copolymer (e.g., Zylar 631® acrylic copolymer).
The devices described herein generally include an atraumatic ocular contact surface at the distal end of the housing. In some variations, the ocular contact surface is fixedly attached to the housing proximal end. In other variations, the ocular contact surface is removably attached to the housing proximal end. The ocular contact surface will typically be sterile. In some instances, the ocular contact surface is disposable. In use, the ocular contact surface of the device is placed on the surface of the eye.
The ocular contact surface may be of any suitable configuration, e.g., size, shape, geometry, etc., as long as it allows atraumatic placement of the device on the ocular surface. In some variations, the ocular contact surface is ring-shaped (e.g.,
More specifically, as shown in the front views of
As shown in
In some variations, the tip of the dispensing member is recessed relative to, and is separated from the closest end of the device housing by a distance ranging from about 0.01 mm to about 10 mm, from about 0.1 mm to about 5 mm, or from about 0.5 mm to about 2 mm.
An enclosure may be provided on the distal end of the device that completely covers the dispensing member to prevent it from contacting eye lashes or eye lids, and to prevent it from being exposed to potentially contaminated surfaces at all times. Here the dispensing member may extend from the enclosure and penetrate the eye wall and into an eye cavity without being exposed to ocular appendages such as eyelids or eye lashes that harbor bacteria. The eye is an immune-privileged organ and, thus, any bacterial contamination has the propensity to result in intraocular infection. Enclosure of the dispensing member may protect it from contacting ocular appendages harboring bacteria, thereby minimizing the risk of sight-threatening intraocular infection. In one variation, the dynamic sleeve (further described below) is configured as the sterile enclosure. The dynamic sleeve may also be covered by a membrane that prevents ocular surface tears from entering the orifice of the device tip and potentially contaminating the dispensing member before it is deployed.
In other variations, the outer surface of the device tip may be configured to include a raised surface that forms a seal around the exit site of the dispensing member from the device tip. The seal may function to prevent ocular tears from circulating through the potential injection site once the device tip has been positioned on the eye surface. The raised surface may be configured to be annular, oval, square, rectangular, triangular or any other suitable shape or geometry.
In another variation, the ocular contact surface of the device tip that comes in direct contact with the eye surface is ring-shaped, where there is a clearing between the internal wall of the device housing and the dispensing member of about 360 degrees, which is marked by arrows in
In some variations, there is a clearing between the internal wall of the device housing and the dispensing member ranging from about 0.1 mm to about 5 mm, from about 0.3 mm to 3 mm, or from about 0.5 mm to about 2 mm.
In other variations, there is a solid membrane or partition (105) that separates the tip of the dispensing member (107) from the external environment, as shown in
Furthermore, the membrane or partition may ensure that the dispensing member tip does not come in contact with any source of accidental bacterial contamination such as tears and ocular secretions prior to the injection procedure, which prevents accidental bacterial contamination of the dispensing member and minimizes the risk of introducing intraocular infection during the intraocular injection procedure that may cause endophthalmitis.
The membrane or partition that separates the tip of the dispensing member from the end of the device housing may comprise a material selected from the group consisting of biocompatible and non-biodegradable materials including without limitation, methylmethacrylate (MMA), polymethylmethacrylate (PMMA), polyethylmethacrylate (PEM), and other acrylic-based polymers; polyolefins such as polypropylene and polyethylene; vinyl acetates; polyvinylchlorides; polyurethanes; polyvinylpyrollidones; 2-pyrrolidones; polyacrylonitrile butadiene; polycarbonates; polyamides; fluoropolymers such as polytetrafluoroethylene (e.g., TEFLON™ polymer); or fluorinated ethylene propylene (PEP); polystyrenes; styrene acrylonitriles; cellulose acetate; acrylonitrile butadiene styrene; polymethylpentene; polysulfones; polyesters; polyimides; natural rubber; polyisobutylene rubber; polymethylstyrene; silicone; derivatives and copolymers and blends thereof.
In some variations, the membrane or partition (30) may be recessed inside the device tip so that when the device tip is placed in contact with any surface such as the skin or the eye surface, the said membrane or partition is separated from the said surface by a distance marked with arrows, as depicted in
The membrane or partition may be recessed relative to and separated from the end of the device housing at the ocular interface by a distance ranging from about 0.01 mm to about 10 mm, from about 0.1 mm to about 5 mm, or from about 0.5 mm to about 2 mm.
In further variations, a measuring component (32) (further described below) may be recessed relative to the end of the device housing (33) at the ocular contact surface (
In some variations, as shown in
In other variations, the ocular contact surface comprises a flange (e.g., FIGS. 3A1-3A3, FIGS. 3B1-3B3,
In some variations, the flange may have thin edges that come in contact with the ocular surface, and which allows the eye lid to travel over and on top of the flange, but prevents the eye lid from coming in contact with the sterile ocular contact surface of the device tip. The ocular contact surface may also be a ring-shaped flange (e.g.,
More specifically, as shown in
In yet further variations, the ocular contact surface may be configured to be flat, convex, concave, or slanted (e.g.,
More specifically, as shown in
The ocular contact surface may include one or more features (e.g., slip-reducing features) that help to stabilize it on the eye surface (e.g., prevent slippage on the eye surface). For example, in one variation, the ocular contact surface comprises one or a plurality of traction elements, e.g., bumps, ridges, raised details above the plane of the ocular contact surface, etc., that increase surface traction of the ocular contact surface on the eye surface without being abrasive. Such an ocular contact surface may provide a mild-, medium-, or high-traction interface to stabilize the device tip on the surface of the eye and prevent it from moving during intraocular drug delivery. In another variation, the ocular contact surface includes an adherent interface such as a suction mechanism. Varying the type of material used to make the ocular contact surface may also help prevent its slippage on the ocular surface.
The materials used to make the ocular contact surface may also help to prevent abrasion, scratching, or irritation of the eye surface. Exemplary non-abrasive materials that may be employed include without limitation, nylon fiber, cotton fiber, hydrogels, spongiform materials, styrofoam materials, other foam-like materials, silicone, plastics, PMMA, polypropylene, polyethylene, fluorinated ethylene propylene (FEP), and polytetrafluoroethylene (PTFE). Thermoplastic elastomers (TPEs), e.g., silicone, may be beneficial to use when making the ocular contact surface. The materials may be smooth-hard, semi-hard, or soft, and may be beneficial in preventing conjunctiva! abrasion, subconjunctival hemorrhage during transcleral needle deployment, or other accidental trauma to the ocular surface tissues (
In some variations, the edges of the ocular contact surface are also rounded to prevent accidental damage to the ocular surface tissues such as the conjunctiva that is covered with delicate non-keratinizing epithelium rich in nerve endings and pain receptors. In this instance, as shown in
The ocular contact surface may also provide an interface surface that is pliable or deformable, and which conforms to the surface of the eye when placed against the said eye surface during the intraocular drug delivery procedure. The surface of the eye that comes in direct contact with the said interface surface of the disclosed device includes, but is not limited to, the surface of the eye over the pars plana region defined as the circumferential area between about 2 mm and 7 mm posterior to and surrounding the limbus, or the corneo-scleral limbal area between about 2 mm anterior and about 2 mm poster to and circumferential to the limbus. The interface surface that conforms to the curvature of the surface of the eye may enable the formation of an optimal contact interface between the device and the eye, and may ensure sterility of the intraocular drug delivery process and immobilization of the eye, which in turn may enhance the safety of the injection procedure. Examples of ocular interface materials for the device are those that are generally able to conform to the surface of the eye (that is deformable or pliable) particularly to the curvature of the external surface of the eye in the area of pars plana about 2-5 mm posterior to the corneo-scleral limbus for intravitreal drug application, as well as to the area of the corneo-scleral limbus for anterior chamber drug applications. As previously stated, materials that are non-abrasive to the non-keratinizing conjunctiva! and corneal epithelium of the ocular surface may be used. Specifically, the materials and their configurations (e.g., foam, braid, knit, weave, fiber bundle, etc.), may include those capable of forming medium- or high-traction surfaces (e.g., hydrogels or cotton) that enable immobilization of the eye globe during the injection procedure.
In some variations, the material of the ocular contact surface changes its properties upon contact with fluid, e.g., by reducing its traction coefficient such as in cotton fiber, which may reduce the risk of conjunctiva! abrasion upon contact of the ocular contact surface with the eye surface. In other variations, the material comprising ocular contact surface does not change its physical and chemical properties when exposed to fluid that covers the surface of the eye such as tears.
The ocular contact surfaces described here may be beneficial in preventing conjunctiva! and/or episcleral bleeding during intraocular needle injection. For example, a device comprising a ring-shaped ocular interface may be pressed against the eye wall, which in turn applies pressure to the conjunctiva! and episcleral vessels, thereby reducing blood flow therethrough. Given the reduced blood flow through these vessels, the risk of subconjunctival bleeding during intraocular injection procedure may be reduced. Following the completion of intraocular drug application, the needle is withdrawn, but the ring-shaped tip may remain pressed against the eye wall, thus applying continuous pressure onto the conjunctiva! and episcleral vessels and further reducing the risk of bleeding and/or minimizing the extent of bleeding.
In some variations, the device comprises an ocular contact surface that functions as a drug reservoir. Here a drug may be incorporated into, or coated on, the material of the ocular contact surface. The drug may then diffuse, leech, etc., from the ocular contact surface onto the surface of the eye. Exemplary materials for inclusion of drugs are hydrogels and their derivatives.
The ocular contact surface may also cover the dispensing member (conduit) such as an injection needle (e.g., it may be a cap that entirely covers the needle), which may enable the injector to apply pressure onto the eye by pressing the tip (e.g., the distal end of the cap) against the eye wall. This in turn may increase the intraocular pressure before the needle comes in contact with the eye wall and, thus, may facilitate needle penetration because the eye wall is more taut in comparison to an eye wall being penetrated by a needle on a conventional syringe. Needle penetration is typically more difficult with a conventional syringe because the lower intraocular pressure that is generated makes the eye wall more deformable and mobile. In addition, the device tip that covers the dispensing member (conduit), such as an injection needle, may also protect the said dispensing member from being contaminated by its accidental contact with eye lids. The cover may be made from any suitable material. Exemplary materials include without limitation, polyethylene, polycarbonate, polypropylene, acrylonitrile butadiene styrene polymers, Delrin® acetal homopolymers, polyurethane, acrylic polymers, polyether ether ketone, and combinations thereof. In one variation, the cover is made from polycarbonate.
The control of intraocular pressure (TOP) during the drug delivery procedure, e.g., intraocular injection or intravitreal injection, may be beneficial. The application of limited intraocular pressure before deployment of the dispensing member (conduit) may reduce scleral pliability, which in turn may decrease any unpleasant sensation on the eye surface during an injection procedure and/or prevent backlash of the device. The term “backlash” typically refers to the inability of the conduit to smoothly penetrate the eye wall due to scleral pliability and elasticity, which makes the sclera indent to a certain point and push the conduit and device backwards before the conduit penetrates into and through the sclera. Accordingly, the devices described here may include one or more TOP control mechanisms, also referred to herein as ocular wall tension control mechanisms. This is because ocular wall tension is proportionally related to, and determined in part, by intraocular pressure. Other factors that may effect wall tension are scleral thickness and rigidity, which can be variable due to patient age, gender, and individual variations.
The TOP mechanisms may control TOP during the placement and positioning of the device tip at the target location on the ocular surface, and/or intraocular or intravitreal positioning of the dispensing member (conduit) during intraocular or intravitreal injection of a drug. For example, the TOP mechanisms may control TOP prior to and during the intraocular or intravitreal positioning of a dispensing member being used for trans-scleral or trans-corneal penetration. Once penetration of the ocular surface by the dispensing member occurs, TOP will typically decrease. This decrease in TOP may occur immediately after penetration of the ocular surface by the dispensing member.
In some variations, the TOP control mechanisms allow (enable) the devices to generate an TOP between 15 and 120 mm Hg during the placement and positioning of the device tip at a target location on the ocular surface, and/or intraocular positioning of the dispensing member. In other variations, the TOP control mechanisms allow (enable) the devices to generate an TOP between 20 and 90 mm Hg during the placement and positioning of the device tip at a target location on the ocular surface, and/or intraocular positioning of the dispensing member. In yet further variations, the TOP control mechanisms allow (enable) the devices to generate an TOP between 25 and 60 mm Hg during the placement and positioning of the device tip at a target location on the ocular surface, and/or intraocular positioning of the dispensing member.
The TOP control mechanisms may also allow (enable) the devices to maintain the TOP between 10 and 120 mm Hg, or between 15 and 90 mm Hg, or between 20 and 60 mmHg during any duration of time of the intraocular injection procedure. In some variations, the drug injection rate is slowed or completely aborted by the device if the intraocular pressure exceeds a certain predetermined value, for example 120 mm Hg, or 60 mm Hg, or 40 mm Hg. Here the TOP control mechanism may be configured to detect a TOP level during the intraocular drug injection of, e.g., 90 mmHg, or 60 mm Hg, or 40 mm Hg.
The TOP control mechanism may include a spring, or it may comprise a mechanical or an electrical control mechanism. In general, the TOP control mechanism will be configured to balance the frictional forces of the injection plunger and fluid injection resistance pressure (force required to push fluid through the needle into the pressurized eye fluids). The TOP control mechanisms may be coupled to the device housing and actuation mechanism in a manner that allows automatic adjustment of the force of dispensing member deployment and plunger advancement. That is, the TOP control mechanism may be configured to affect a predetermined level of force of the dispensing member and a predetermined intraocular pressure level. Again, use of the TOP control mechanisms may generate higher than the resting TOP prior to dispensing member deployment so that scleral elasticity and the potential for device backlash is decreased, and to facilitate scleral penetration by the dispensing member.
In one variation, the TOP control mechanism is a pressure relief valve that bypasses the injection stream once a maximum pressure is reached. In another variation, the TOP mechanism is a pressure accumulator that dampens the TOP within a specified range. Some variations of the TOP control mechanism may include a pressure sensor. In yet another variation, the TOP control mechanism includes a slidable cap or shield that covers the dispensing member prior to its deployment, but which may slide or retract along the surface of the device housing to expose, deploy, or advance the dispensing member e.g., upon attainment of a predetermined TOP level. Sliding of the cap may be manually adjustable, e.g., using a dial, or automatically adjustable, step-wise, or incremental in nature. For example, as shown in
A locking mechanism may also be used to prevent sliding of the cap, cover or ocular contact surf ace, or prevent deployment of the dispensing member until a predetermined TOP is 32 reached. The locking mechanism may also be used to prevent sliding of the cap, cover, or ocular contact surf ace if a predetermined TOP is not reached. For instance, the locking mechanisms included on the devices described here that include a slidable cover, cap, etc., may be released manually or automatically when the TOP reaches a predetermined level, such as between 20 mm Hg and 80 mm Hg. Such locking mechanisms may include without limitation, high traction surfaces, locking pins, interlocking raised ridges, or any other type of locking mechanism that prevents the tip of the device, e.g., the cap or cover of the device, from sliding and thus exposing the needle.
In yet further variations, the TOP control mechanism includes a high-traction surface or raised ridges on the cap, cover, shield, or ocular contact surface situated over the dispensing member. Such features may be disposed on the inner surface of the cap, cover, shield, or ocular contact surface and configured so that upon sliding in the proximal direction, the high-traction surface or raised ridges mate with corresponding structures (e.g., crimps, dimples, protrusions, other raised ridges) on the surf ace of the device housing or other appropriate device component to provide resistance of the cap, cover, shield, or ocular contact surface against the eye wall (thus increasing ocular wall tension and IOP). In this instance, the IOP control mechanism comprises a resistance component, as further described below. As stated above, the cap, cover, shield, or ocular contact surface may be configured so that sliding is manually or automatically adjustable, step-wise, or incremental in nature. When raised ridges are employed, any suitable number may be used, and they may be of any suitable size, shape, and geometry. For example, the raised ridges may be circumferentially disposed within the cap, cover, or ocular contact surface. In some instances, the raised ridges are configured with surfaces of differing slope. For example, the distal surface may be configured to be steeper than the proximal surface. With this design, incremental sliding and incremental increases in TOP may be generated when the cap, cover, shield, or ocular contact surface is slid proximally, but sliding of the cap, cover, shield, or ocular contact surface back over the dispensing member may also be accomplished due to the decreased slope of the proximal ridge surface.
TOP control mechanisms that provide resistance may slide and expose a needle secured to the housing, e.g., a syringe, when the force exerted on the shield is transmitted onto the eye wall. The exerted force may create an intraocular pressure of between about 10 mmHg to about 33 150 mm Hg, between about 12 mm Hg and about 120 mm Hg, between about 15 mm Hg and about 60 mm Hg, or between about 15 mm Hg and about 40 mm Hg.
The application of pressure to the surface of the eye may be accomplished and further refined by including a resistance component, e.g., a dynamic resistance component to the injection device. The dynamic resistance component may be configured to detach from the injection device. The dynamic resistance component may include a slidable element and/or a fully rotatable (e.g., rotate 360 degrees) or partially rotatable (e.g., rotate less than 360 degrees) element coupled to the housing. The dynamic resistance component may be configured so that it can be fully or partially rotated about the long axis of the device using only one finger (e.g., the middle finger) while holding the device with the thumb and the index finger of the same hand. In some variations, the slidable element comprises a dynamic sleeve configured to adjust the amount of pressure applied to the eye surface, as further described below. As previously stated, certain variations of the ocular wall tension control mechanism function as dynamic resistance components. A force between about 5 gm to about 100 gm or about 10 gm to about 30 gm may be needed to initiate movement of the slidable elements against resistance that is generated by the slidable elements. In some variations, it may take about 20 gm to about 25 gm of force to initiate movement of the slidable elements. In other variations, it may take about 3 gm to about 30 gm of force to initiate movement of the slidable resistance component.
The dynamic resistance component may also be configured as a dynamic sleeve. Similar to the slidable cap previously described, the dynamic sleeve may be configured to increase intraocular pressure and tension of the eye wall prior to needle injection. However, the dynamic sleeve is capable of being manually manipulated to thereby adjust the amount of pressure applied on surface of the eye (and thus, the amount of eye wall tension). Having the ability to manually adjust the applied pressure may allow the injector (user) to have improved control of the injection site placement and the injection angle, and also enhances the user's ability to stably position the device on the ocular surface prior to needle deployment. In general, the dynamic sleeve is designed to enable the user to precisely position the device tip at the targeted site on the eye surface and to firmly press the device tip against the eye wall to increase 34 wall tension and intraocular pressure. The dynamic sleeve may be used to raise intraocular pressure to a predetermined level, as described above, prior to the initiation of sleeve movement and needle deployment. It should be understood that the terms “dynamic sleeve,” “sleeve,” “slidable sleeve,” “dynamic sleeve resistance control mechanism,” and “sleeve resistance mechanism” are used interchangeably throughout. In some variations, the dynamic sleeve is removable or detachable from the drug conduit, rendering the drug conduit completely uncovered. In other variations, the dynamic sleeve is fixedly attached to the drug conduit and at least partially covers the conduit. In yet further variations, the dynamic sleeve may be rigid or non-deformable. The dynamic sleeve may be configured such that when a pulling force (e.g., retraction away from the eye) is exerted on the sleeve, this movement may facilitate needle exposure and reduce the amount of pressure force (down to 0 Newton) (“N” refers to the unit of force “Newton”) needed to be applied to the eye wall in order to slide the sleeve back and expose the needle. The dynamic sleeve may also be configured such that when a pushing force (e.g., advancement) is exerted on the sleeve, this movement may counteract and impede needle exposure, which may allow the device tip to apply increased pressure to the eye wall prior to the initiation of sleeve movement and needle exposure.
Some variations of the dynamic sleeve provide a variable force that follows a U-shaped curve, as described further in Example 1 and
Variable traction force may also be provided by components such as circular raised bands or ridges on the outside surface of the device tip. These components may provide countertraction when approximated against another circular raised band or ridge on the inside surf ace of the movable dynamic sleeve (inner bands or ridges). When the outer and inner bands or ridges are in contact with each other before the dynamic sleeve begins to move, they generate high traction and high resistance to dynamic sleeve movement. Once the dynamic sleeve starts to move, the raised band on the outside of the device housing moves past the raised band on the inside of the dynamic sleeve, which may result in a rapid decrease in resistance to dynamic sleeve movement and, therefore, decreased pressure on the eye wall by the device tip. The shape of the raised interlocking bands or ridges will generally determine the shape of resistance decrease. For example, the resistance decrease may follow a sine-shaped profile.
The resistance component may also be configured as a slidable shield that is coaxial with housing, and which has a lumen and an internal surface that forms a raised step or platform about at least a portion thereof. In some variations, the step or platform circumscribes the entire lumen of the slidable shield. The luminal diameter of the slidable shield is generally reduced in the area of the step or platform to thus provide higher friction (resistance) when the shield slides along the housing. Thus, the internal diameter of the slidable shield may typically be smaller in its distal portion than in its proximal portion. The width of the raised step or platform may be from about 0.1 mm to about 5 mm, or from about 0.5 mm to about 2 mm. The raised step or platform may also have at least one rounded or sloped edge, e.g., either the proximal or distal edge, or both edges. The raised step or platform may further include an edge that is gradually sloped to achieve a gradually increase the diameter of the lumen and generate a smooth reduction in friction as the slidable shield moves to expose the needle. For example, the edge can be sloped so that the lumen is greater in the proximal portion of the shield than at its distal portion.
In another variation, the dynamic sleeve may generate a force that continuously decreases from its highest point before needle deployment (when the dynamic sleeve completely covers the needle), to its lowest point when the dynamic sleeve begins to move to expose the needle tip. Here the force remains low until the end of dynamic sleeve travel and complete needle deployment. This pattern of resistance decrease may follow a sine-shaped curve.
Slidable advancement of the dynamic sleeve may generate a resistance force against its movement ranging from ON to about 2 N. In some instances, slidable advancement of the dynamic sleeve generates a force ranging from about 0.1 N to about 1 N. As previously stated, the amount of force that may be required to move the sleeve may range between about 3 gm and about 30 gm.
The resistance component may be configured to be part of an injector attachment or injector assembly that can be removably attached to any suitable syringe, including syringes of the luer lock and luer slip type. The resistance component of the injector attachment may interface with the internal surf ace, external surface, or both surfaces of a slidable sleeve. In some variations, the injector attachment comprises a ring or disc-shaped component that at least partially surrounds the exterior of, and is raised above the surface of the injector attachment. The 37 ring may function as a backstop for the slidable resistance component and/or as a grip or handle to help manipulate the injector attachment on and off the syringe. As shown in
In some instances, the resistance component may include a plurality of appendages attached to, or formed as part of, the needle hub. Here the device may be generally configured to include an injector attachment that can be exchanged for the loading needle of a typical syringe. The injector attachment may include a sterile injection needle (e.g., a 30 to 33 gauge needle) and a resistance component (e.g., a dynamic sleeve). An advantage of this modular design may be that side-loading of drug into the device drug reservoir is no longer needed because the device can be loaded like a regular syringe. Such a modular assembly may contain a universal female connector comprising, e.g., a flange, at the proximal portion of the attachment. The female connector may enable the injector attachment to removably interface (i.e., attach and detach) with a male luer-tip drug reservoir. The drug reservoir may be a syringe that includes a luer fitting of the luer lock or luer slip configuration, or any derivative or modification of the luer tip. The modular design may enable loading of a drug reservoir within any of the devices described herein with a drug from a container, e.g., a drug vial. A loading needle can first be used to transfer the drug from the vial to the reservoir. The loading needle may then be detached or switched for an injector attachment.
For example, as shown in
However, not all the projections (1504) may be used to provide resistance to shield (1506) movement. Any number of the projections (1504) included may be used to provide resistance. For example, just one or two projections out of four may be used to provide resistance. Projections not used to provide resistance may provide forward and rearward sliding 39 limits for the shield, and may also prevent the shield from rotating relative to the syringe axis. Needle (1514) is attached to the hub (1502) and extends distally therefrom. The force and resistance curves, decreases in resistance, and the amount of force generated between the projections and the slidable shield may be the same or similar to that described for the dynamic sleeve.
One or more longitudinal grooves may also be placed on the internal surface of the slidable sleeve. The grooves may extend through either a partial-thickness or a full-thickness of the sleeve's wall. Thus, the projections from the hub (or needle assembly or housing) travel within the grooves to prevent the sleeve from spinning/rotating around its long axis. In one variation, the grooves preventing the rotation of the sleeve may be useful when the measuring component covers the 360 degrees of circumference of the tip (i.e., when there is no need to rotate the sleeve to orient the measuring component towards the limbus).
The injector attachments may be made by bonding the needle to a needle hub configured with a plurality of projections. A shield such as the one shown in
Some variations of the safety clip generate resistance that impedes the movement of the shield relative to the drug conduit. For example, the clip could lock the shield in a certain position or more than one position (such as pre-deployment resting position, post-injection end position, or both), and may prevent the movement of the shield relative to the drug conduit. In one variation, the safety clip does not rotate relative to the long axis of the device. In another example, the safety clip may be rotatable relative to the long axis of the device.
Another variation of the injector attachment is shown in
A clip (1607) may be provided on the needle hub (1610) for preventing axial movement of the shield (1618) along the outer surface of the needle hub (1610). Axial movement of the shield (1618) can occur when the clip (1607) is removed. The clip may be a safety feature that prevents the resistance component, e.g., the slidable shield from longitudinally moving along the axis of the device. The clip may be of any suitable configuration that prevents axial movement of the shield when coupled to the needle hub, and which allows axial movement when removed from the needle hub. In some variations, the clip may be locked to the device housing or the needle hub assembly so that it does not rotate about the housing (e.g., about the longitudinal axis of the device). However, in other variations, the clip may be configured to be rotatable about the housing. In some variations, as further described below, a locking mechanism, such as a clip, that controls the mobility of the dynamic shield or sleeve is non-removably attached to the 41 devices housing, the shield, needle hub/assembly, drug reservoir, or any part of the device. For example, the locking mechanism may be released by pressing its rear lever, thus releasing the slidable shield and rendering it mobile.
Although the clip is shown as comprising a looped body portion and tabs in the figures, it may be of any suitable configuration. For example, the body portion may have a width between about 1 mm and about 12 mm, between about 3 mm and about 10 mm, or between about 4 mm and about 8 mm. The clip may be made from any suitable material. Exemplary materials include without limitation, polyethylene, polycarbonate, polypropylene, acrylonitrile butadiene styrene polymers, Delrin® acetal homopolymers, polyurethane, acrylic polymers, polyether ether ketone, and combinations thereof. In one variation, the clip is made from polyethylene.
Clips or levers that are fixed or non-removably attached to a portion of the injector device or injector attachment could also be employed. These clips or levers could be of any suitable configuration that prevents movement of the resistance component. Some variations of the clip or lever may be fixed to the device housing, while others may be fixed to a portion of the needle assembly. For example, as shown in
In one variation, the lever-actuation tab is a release tab that releases the locking action of the lever when a pressure force is applied to the tab rendering the slidable shield covering the needle mobile. In another variation, the lever-actuation tab is a locking tab that locks the slidable 42 shield when a pressure force is applied to the tab rendering the slidable shield covering the needle immobile. In one variation, the lever-actuation tab is located on one end of the lever (e.g. either front or rear end of the lever). In another variation, the lever-actuation tab is located on both ends of the lever. In its locked position (
In one variation, the lever may have a built-in bias toward the shield-immobilizing position. In one example, when no external pressure force is applied to the lever's release tab, the lever exerts a certain resistance on the slidable shield, which prevents the shield from moving backward and exposing the needle tip.
In another variation, the lever may have two equal positions without any bias, one shield-immobilizing position and the other shield-mobilizing position. For example when the release end (e.g. the rear end) of lever is depressed, the lever unlocks the slidable shield's anterior-posterior movement (i.e. mobilizes the shield) and the shield remains mobilized until external pressure is applied to the front end of the lever (e.g. the front end of the lever may be manually depressed or the rear end of the lever may be lifted), thus the lever exerts no built-in bias for either shield-immobilizing or shield-mobilizing position.
In yet another variation, the lever may have a built-in bias toward the shield-mobilizing position, such as when no external pressure force is applied to the lever, the lever exerts no resistance on the slidable shield rendering it freely mobile in anterior-posterior direction unless an external pressure force is applied to the lever, which locks the slidable shield rendering it immobile but only while the external pressure force is being applied to the lever. 43
In one variation, the lever or clip may permanently lock the slidable shield rendering it permanently immobile at the end of the injection procedure reducing the risk of an accidental needle stick and facilitating safe disposal of the device. This may be achieved, for example, by applying an external pressure force to the front end of the lever or twisting the slidable shield around its long axis in order to lock the front tip of the lever to the slidable shield through, for example, a slot, groove or a hole in the slidable shield rendering the slidable shield immobile in the anterior-posterior direction.
In one variation, the lever may have a combination of the built-in bias and at least one or two lever-locked positions. For example, a locked-down position may increase resistance to sliding movement or completely immobilizes the slidable shield. In another example, a lockedup position may decrease resistance to sliding movement or completely mobilizes the slidable shield rendering it freely mobile along the needle's long axis. The above lever-locked positions may be maintained when there is no external pressure force applied onto the lever.
The lever may comprise a lever-positioning mechanism, for example a flexible arm connector (PAC) (7000), as shown in
The PAC may also provide resistance to bending and positional memory enabling a certain pre-determined positional bias of the lever (7002). For example, the PAC (7000) may return the lever (7002) into its shield-locking position when there is no external force applied onto the lever, thus re-locking and/or immobilizing the slidable shield (7006).
The PAC (7000) may also control and/or regulate the amount of force required to unlock the resistance component, e.g., slidable shield (7006). In one variation, a PAC may regulate the slidable shield's sliding movement by gradually increasing or decreasing the resistance against the shield's movement, for example if the lever is only partially engaged with the shield providing partial resistance to shield's sliding movement, e.g., through an interference 44 fit. Thus, the lever may comprise or be part of the “resistance component,” described elsewhere herein.
As further illustrated in
The clip or lever may comprise a resistance component, a safety feature, or a combination thereof that prevents the resistance component, e.g., the slidable component such as a shield or sleeve from longitudinally moving along the axis of the device. For example, the clip may prevent the slidable component from moving relative to the drug conduit in the predeployment or resting state. In some variations, the clip may prevent the slidable component from moving relative to the drug conduit in both pre-deployment and post-injection states when the tip of the drug conduit, for example an injection needle, is completely covered by the slidable component such as a shield or a sleeve. In some variations, the clip may create resistance to and partially or completely hamper the back and forth mobility of the slidable component relative to the drug conduit in at least one or both pre-deployment and post-injection states when the tip of the drug conduit is completely covered.
The eye is a unique organ in that it is shaped as a hollow sphere that has certain intraocular pressure (TOP) normally maintained within a certain range that increases when external pressure is applied onto the eye wall and may cause tissue damage or intraocular arterial and/or venous occlusions. In addition, the eye is exquisitely sensitive to external pressure that may cause substantial discomfort for the individual in the form of photopsia, uncomfortable pressure sensation and/or pain, which may be difficult to completely abolish even by topical anesthesia. Thus, there is a need for a mobility control mechanism that controls the mobility of a slidable component that protects the tip of a drug conduit, such as the injection needle, while the 45 device is placed onto the eye wall, while controlling the level of pressure applied onto the eye wall. Such a mechanism enables stable and safe placement of the intraocular drug delivery device onto the eye surface while the slidable component is locked and non-mobile in the needle pre-deployment state, but without applying excessive pressure onto the eye wall. The mechanism may be gradually or completely released to partially or completely remove the lock on the slidable component rendering it partially or freely mobile in the needle deployment state during intraocular injection. Thus, the mobility control mechanism enables manual control of the slidable element's mobility ranging from it being completely locked and immobile to being partially mobile with certain resistance, to being completely and freely mobile relative to the drug conduit. For example, the slidable component may be non-mobile in the pre-deployment and post-injection states but freely or partially mobile during the injection state by completely or partially releasing the mobility control mechanism, for example by manually pressing on the rear lever of the control mechanism thus lifting its front locking part. The mobility control mechanism ensures that the drug conduit, such as an injection needle, is not deployed or exposed prematurely before the device is properly positioned in the desired location of the eye surface. In other variations, it may also ensure that the slidable shield or sleeve securely covers the tip of the drug conduit at the end of the injection procedure preventing accidental needle sticks.
In some instances, the proximal end of the slidable shield comprises a centration/stabilization element, such as a band or ring having a certain thickness and its internal lumen diameter smaller than the remainder of the proximal portion of the slidable shield. The centration/stabilization enables a snug interface between the slidable shield and the needle hub assembly or device housing, thus stabilizing and centering the slidable shield relative to the long axis of the device during its travel. In one example, the centration/stabilization element is attached to the internal surface of the proximal end of the slidable shield. The slidable shield may have slots provided through the wall, or partially through the wall, of the shield. The slots may have any suitable size, shape, and geometry, and will typically be configured to interface with the slots in a complimentary manner.
In yet a further variation, as shown in
In some instances, the internal diameter of the narrower portion of the slidable shield may be substantially similar to the external diameter of a needle holder (4012) (e.g., see
Alternatively, resistance or friction force may be generated by the friction between the drug conduit (e.g., a needle) and the conduit's tunnel (e.g, needle tunnel), device tip, or ocular contact surface. For example, the resistance or friction force may be generated between the shaft of the drug conduit and the material comprising the device tip and/or ocular contact surface.
In one variation, the resistance component comprises a combination of an external resistance component (e.g., a resistance lever that releaseably immobilizes a slidable shield described herein) and an internal resistance component (e.g., friction between the drug conduit and its tunnel or between the needle hub assembly and the slidable shield).
As further shown in
As previously stated, the benefit of the injector attachment is that it can be used with commercially available syringes, e.g., tuberculin or insulin syringes. Drug may first be loaded 47 into the syringe in the usual manner using a standard loading needle instead of through a side port. The standard needle may then be removed and an injector attachment, as described herein, placed on the luer slip at the distal end of the syringe. The clip may then be removed to free the shield and allow it to axially move along the surface of the needle hub. The ocular contact surface (e.g., with measuring component) may then be placed on the surface of the eye. Next, the syringe body may be advanced to advance the needle into the eye. During this syringe advancement step, the projections on the needle hub generally slide within the shield distally (toward the ocular contact surface). The shield may also slide proximally (toward the proximal end of the needle hub) due to the initial wall tension of the ocular surface. The resistance to sliding of both the needle hub and shield may be adjusted or manipulated based on the particular structure or configuration of the projections extending from the shield. The needle is prevented from being advanced any further once the tabs on the distal ends of the projections snap into the slots in the wall of the shield. The needle may be advanced from between about 1 mm to about 25 mm, or from between about 2 mm to about 8 mm, into the eye before the slots are reached. Drug may then be injected into the eye using the plunger of the syringe and then the syringe and needle removed from the eye.
In variations where the resistance component comprises a slidable shield/sleeve, the resistance component may function to protect the sterility of the drug conduit, e.g., a needle. The slidable shield may protect needle sterility by protecting it from accidental contact with and contamination from, the eyelids, eyelashes, ocular surface secretions, and/or airborne pathogens. The slidable shield/sleeve may also function to protect the needle from contamination by the eyelids and lashes when the patient blinks. Further, the slidable shield/sleeve may function to prevent or minimize the circulation of non-sterile secretions and tears over the injection site.
The devices described here may include a measuring component that may be useful in determining the location of the intraocular injection site on the eye surface. Some variations of the device may include an ocular contact surface having a high-traction surface integrated with a measuring component. The measuring component may be fixedly attached or removably attached to the ocular contact surface. The measuring component may also be configured to fully (360 degrees) or partially rotate (less then 360 degrees) about the long axis of the device 48 housing. Inclusion of a rotatable (dynamic) measuring component may allow the operator to maintain a comfortable grasp of the device without having to change or reposition the finger placement pattern in order to appropriately orient the measuring component toward the limbus in any meridian either in the left or right eye of a mammal (for example perpendicular to the limbus), in order to accurately determine the injection site and before stably positioning the device tip on the eye surface. A rotating (dynamic) measuring component may also enable sterile localization of injection site in any meridian/clock hour relative to limbus circumference, while avoiding contact with the eyelids or eyelashes.
In some variations, the measuring component comprises one or a plurality of measuring elements or tabs radially extending from the proximal device tip comprising an ocular contact surface. The radial measuring elements or tabs may be oriented perpendicular to the circumference of the proximal device tip comprising an ocular contact surface. In one variation, the measuring component comprises, 1-12, or 3-9, or 6-8, or 6 radially oriented measuring elements or tabs.
In one variation, the measuring component spans the entire circumference of the proximal device tip comprising an ocular interface surface. In another variation, the measuring component spans a portion of the circumference of the proximal device tip comprising an ocular interface surface.
In one variation, the angle between any two adjacent radial elements is the same and constant. In some examples, the angle between any two adjacent radial elements is between 180 degrees and 15 degrees, or between 35 degrees and 25 degrees, or about 30 degrees.
In another variation, all radially oriented elements have equal lengths. In another example, at least some of the radially oriented elements have different lengths. In one example, the lengths of the radially oriented elements vary between 1 mm-6 mm, or between 3.5 mm-4 mm.
As previously stated, the measuring component may be raised above the ocular surface so that it prevents the eye lid from coming in contact with the sterile ocular contact surface of the device tip (e.g.,
In general, the measuring component will enable the intraocular injection site to be more precisely placed at a specific distance from, and posterior or anterior to, the corneal-scleral junction termed “the limbus.” In some variations, the measuring component may provide for placement of the intraocular injection site from about 1 mm to about 5 mm, from about 2 mm to about 4.5 mm, or from about 3 mm to about 4 mm, from and posterior to the limbus. In another variation, the measuring component may provide for placement of the intraocular injection site from about 2 mm to about 5 mm posterior to the limbus, or about 3.5 mm posterior to the limbus. In other variations, the measuring component may provide for placement of the intraocular injection site from within about 3 mm or about 2 mm, from and anterior to, the limbus, or between about 0.1 mm and about 2 mm from and anterior to the limbus. In one variation, the measuring component provides for placement of the intraocular injection site between about 1 mm anterior to the limbus and about 6 mm posterior to the limbus. In another variation, the measuring component provides for placement of the intraocular injection site between about 3 mm to about 4 mm posterior to the limbus.
The measuring components may have any suitable configuration. For example, the measuring components may be located on one side of the ocular contact surface or on more than one side of the ocular contact surface (e.g.,
In alternative variations, the measuring component comprises one or more members (e.g.,
More specifically, as shown in
More than one measuring component is also shown in
Alternatively, the measuring components may be configured as one or more flexible measuring strips. Flexible materials that may be used to make the measuring strips include flexible polymers such as silicones. As shown in
In some variations, the measuring component may be configured as a marking tip member (97). As shown in
In further variations, the measuring component may be a sectoral measuring component. The sectoral measuring component may be configured to span a sector of between about 1 degree and about 180 degrees of arc (e.g., between about 45 degrees and 90 degrees of 53 arc) at the distal end of device or housing. In general, by “sectoral” it is meant that only a portion or section of the measuring component includes elements for taking measurements. For example, a sectoral measuring component may include radially extending members that are spaced from about 1 degree to about 90 degrees about the circumference of the device tip. During precise localization of the injection site, a sectoral measuring component configured in this manner may enhance sterility of the procedure because the measuring component can be oriented toward the limbus and away from periocular appendages such as the eyelids and eye lashes. Here the sectoral measuring component may avoid contact with the appendages, thus minimizing the risk of bacterial contamination and intraocular infection, while enabling precise localization of the injection site relative to the limbus in a sterile manner.
In one variation, the sectoral measuring component may comprise a central (core) member having a proximal end and a distal end, and comprising a plurality of radially oriented spokes or tabs as the radially extending members, which are equal in length. Central member may be round, oval, square, rectangular or triangular in shape having a circumference or a perimeter. When central member is round, its diameter may be between about 1.0 mm and about 8.0 mm, or between about 3.0 mm and about 6.0 mm. Radially extending members may have the same fixed angle between any two adjacent members, for example, between 1 degree and 90 degrees, or between 15 degrees and 45 degrees. The radially extending members may also have the same length, so that the distance between the needle exit point and the tip of each individual radial member tip is substantially the same, for example between about 1.0 mm and about 5.0 mm, or between about 3.0 mm and about 4.0 mm. With this configuration, the sectoral measuring component may provide fine adjustment of device positioning on the ocular surface around the limbus circumference while rotating the entire device between 1 and 180 degrees (or between 1 and 90 degrees) and using any one or plurality of spokes or tabs to measure the distance between injection site and the limbus. As shown in
In another variation, three divergent measuring tabs or spokes may comprise the measuring component. In a further variation, two divergent measuring tabs or spokes may comprise the measuring component. The divergent measuring tabs or spokes may span a curvilinear distance between about 30 degrees and about 180 degrees or between about 45 degrees and about 90 degrees on the distal surface of the device tip. Having the measuring tabs or spokes protrude only on one side of the device tip that is oriented towards the limbus and away from the eyelid may be helpful in ensuring that the measuring tabs do not become contaminated by touching the eyelids or eyelashes.
In yet another variation, the measuring component, e.g., one having tabs or spokes as described above, may be configured to form a device tip that couples to a slidable shield by an interference fit. For example, as shown in the cross-sectional view of
The intraocular drug delivery devices described here may include any suitable conduit (or dispensing member) for accessing the intraocular space and delivering active agents therein. The conduits may have any suitable configuration, but will generally have a proximal end, a distal end, and a lumen extending therethrough. In their first, non-deployed (pre-deployed) state, the conduits will generally reside within the housing. In their second, deployed state, i.e., after 55 activation of the actuation mechanism, the conduit, or a portion thereof, will typically extend from the housing. By “proximal end” it is meant the end closest to the user's hand, and opposite the end near the eye, when the devices are positioned against the eye surface. In some variations, the drug conduit is removable or detachable from the drug reservoir. In other variations, the drug conduit is permanently (fixedly attached) to the drug reservoir.
The distal end of the conduit will generally be configured to be sharp, beveled, or otherwise capable of penetrating the eye surface, e.g., the sclera. The conduit employed may be of any suitable gauge, for example, about 25 gauge, about 26 gauge, about 27 gauge, about 28 gauge, about 29 gauge, about 30 gauge, about 31 gauge, about 32 gauge, about 33 gauge, about 34 gauge, about 35 gauge, about 36 gauge, about 37 gauge, about 38 gauge, or about 39 gauge. The wall of the conduit may also have any suitable wall thickness. For example, in addition to regular wall (RW) thickness, the wall thickness of the conduit may be designated as thin wall (TW), extra/ultra thin wall (XTW/UTW), or extra-extra thin wall (XXTW). These designations are well known to those of skill in the relevant art. For example, the conduit may be a fine gauge cannula or needle. In some variations, the conduits may have a gauge between about 25 to about 39. In other variations, the conduits may have a gauge between about 27 to about 35. In yet further variations, the conduits may have a gauge between about 30 to about 33. Use of a small needle gauge, for example a 31-33 gauge needle, may make the needle track through the sclera smaller and may minimize the risk of the drug backflow from the eye along with the egress of intraocular fluid following intraocular needle withdrawal.
In some variations, the outer diameter of the needle may be tapered from a wider needle base toward a narrower needle tip. In another example, the needle inner diameter may be tapered from a wider needle base toward a narrower needle tip. In yet another example, both the needle outer and inner diameters may be tapered from a wider needle base toward a narrower needle tip. For example, either or both needle diameters may be tapered from about 25 to about 27 gauge at the base toward about 31 to about 33 gauge at the tip, or from about 30 gauge at the base toward about 32 to about 33 gauge at the tip.
The conduits may have a sharp, pointed tip (
The sharp, pointed needle tip may provide improved penetration of the needle through the fibrillar, fibrous scleral tissue, which is the major structural cover of the eye and consists of a network of strong collagen fibers. Thus, such a needle tip during its penetration through the eye wall may create less resistance and, thus, decrease the impact force that is transmitted to the intraocular structures, such as the retina and the crystalline lens, in turn causing less damage to intraocular structures during the intraocular injection process (compared to conventional needles).
In addition, such a narrow bevel angle may enable the needle to cause less sensation when it penetrates through the eye wall (the outer cover of the said eye wall being richly innervated with sensory nerve fibers endings particularly densely located in the conjunctiva and cornea), which may be an issue when intraocular injections are involved compared to other less sensitive sites.
The narrow bevel angle may also allow for a longer bevel length and larger bevel opening and, thus, a larger opening at the distal end of the injection needle. With such a configuration, the force of drug injection into an eye cavity may be reduced, thus reducing the chances of intraocular tissue damage by a forceful stream of injected substance, which may occur with conventional short-beveled needles.
In some variations, the conduits are injection needles having one or more flat surface planes, as well as one or more side-cutting surfaces, as illustrated in
In other variations, the conduit may be configured to be wholly or partially flattened in at least one dimension, as shown in the cross-sectional view of
As previously stated, in its second, deployed state, the conduit or needle extends from the housing. The portion of the needle that extends from the housing can be referred to as the exposed needle length. Upon activation of the actuation mechanism, the needle goes from its first, non-deployed state (pre-deployed state) (where it is entirely within the housing of the device), to its second, deployed configuration outside the housing, where a certain length of it is exposed. This exposed length may range from about 1 mm to about 25 mm, from about 2 mm to about 15 mm, or from about 3.5 mm to about 10 mm. The exposed needle lengths may enable complete penetration through the eye wall and into the vitreous cavity, while minimizing the risk of intraocular damage. The exposed needle length may be adjusted according to the depth of needle penetration desired. In some variations, the exposed needle length ranges from about 1 mm to about 25 mm, or from about 1.5 mm to about 10 mm, or from about 2 mm to about 8 mm. Here the exposed needle lengths may enable complete intraocular penetration through the cornea into the anterior chamber, while minimizing the risk of intraocular damage. To illustrate, if the injection depth is too shallow, the drug could be injected into the choroid causing bleeding, or into the cortical gel causing a retina tear. If the injection is too deep, the jet stream or hydraulic wave generated by the injected drug could cause trauma to the lens or the retina/macula on the opposite side of the eye. An exemplary range of needle exposure past the external surface of the 58 device tip is between about 4 to about 6 mm, or between about 2 to about 8 mm, or between about 1 mm to about 25 mm. If the injection depth is too shallow, the drug may leak out of the eye due to backflow of the intraocular fluid through the needle track. This may result in variable intraocular drug concentration following injections. To minimize this, it may be beneficial for the needle to (be exposed and) have a penetration depth of at least about 2 mm (or at least about 4 mm, or at least about 6 mm), and have a small needle gauge that may produce a self-sealing wound (for example 30 gauge or smaller, or in the range of 30-33 gauge).
In some variations, the devices may include an exposure control mechanism (9) for the dispensing member (11) (conduit) (
The devices may also include a removable distal (towards the eye) member that covers and protects the conduit (e.g., the front cover (15) in
Some variations of the devices described herein comprise a needle stabilization mechanism or needle guide mechanism configured to provide a steady and consistent needle alignment that is perpendicular to the ocular contact surf ace, and, therefore, perpendicular to the eye surface. This allows the operator to precisely control the angle of needle penetration into the eye by controlling the position of the device tip and housing relative to the eye surf ace. For example, the needle stabilization mechanism may be configured so that the needle exits the device tip through its central point (e.g., at the geometric center of a round tip) at 90 degrees 59 relative to the tip outer surface (e.g., the ocular contact surface). Referring to
In addition to allowing the injection needle to remain centered with respect to the injection device during the injection procedure, the needle stabilization mechanism may also be configured to include an anti-bending component that prevents bending of the needle while it is being advanced into the eye. In some variations, the needle stabilization mechanism is made of a non-deformable material, such as polycarbonate. In other variations, the needle stabilization mechanism is part of the slidable shield, or may be detachable or fixedly connected to the shield.
A drug conduit such as a needle used with the devices described herein may bend at its base (e.g., where it is inserted into the hub) or near the center of the needle shaft during advancement through the eye wall. The needle stabilization mechanism may be configured to support the needle as it is being deployed. Thus, the needle stabilization mechanism may have a certain length and/or inner diameter relative to the enclosed drug conduit. In general, the needle stabilization mechanism will have a minimal (and optionally uniform) length and/or maximum inner cross-sectional diameter. The needle stabilization mechanism may also be defined by a ratio of its length to its inner cross-sectional diameter (to distinguish an opening in a shield that would be relatively short). As previously mentioned, the needle stabilization mechanism may have a certain length and/or inner diameter (ID) relative to the dimensions of the enclosed drug conduit. For example, the needle stabilization mechanism may have an axial length of between about 5% to about 95%, about 20% to about 60%, or about 20% to about 50% of the needle axial length. In some variations, the needle stabilization mechanism has an ID ranging from about 30% to 100%, from about 50% to about 95%, or from about 50% to about 90% of the outer 60 diameter (OD) of the drug conduit. In one variation, the ID of the needle stabilization mechanism is greater than the OD of the drug conduit. The needle stabilization mechanism or guide mechanism may allow the utilization of smaller gauge needles or larger gauge but thinner walled needles (as compared to conventional needles), which may be particularly beneficial when large molecular drugs that include peptides, proteins, antibodies, soluble receptors, etc., are delivered. In some variations, such a needle stabilization mechanism may be configured as a tunnel, sheath, or scabbard in which the needle is coaxially disposed. The needle may be completely covered inside its needle stabilization mechanism during the resting position. During needle deployment, about 4 mm to about 10 mm of the needle tip may be exposed outside of the needle stabilization mechanism. Furthermore, the needle stabilization mechanism may be configured so that the needle travels directly through it and into the eye without contacting air.
The central positioning and anti-bending features of the needle stabilization mechanism may be particularly beneficial in preventing bending of smaller gauge needles, for example 31 gauge to 35 gauge needles. The utilization of smaller gauge needles is particularly desirable for intraocular injections because the opening such a needle makes in the eye wall is smaller, thereby eliminating or reducing the back flush of intraocular fluid following needle withdrawal. Eliminating or reducing the backflush of intraocular fluid has other advantages. For example, communication between the outside environment and the interior of the eye is avoided or minimized (or the time period that the communication exists is eliminated or reduced), in turn reducing the risk of intraocular infection or endophthalmitis. Additionally, the use of a smaller needle gauge enhances patient comfort during intraocular needle penetration, which is inversely proportional to the needle gauge. Furthermore, the anti-bending and central positioning features are also beneficial when thin walled needles are utilized for intraocular drug delivery of high viscosity, high molecular weight, or large particle drugs.
When a shielded drug conduit (e.g., an injection needle) is completely covered inside its shield, a priming solution, gel, or suspension (e.g., a drug) may drain back into the cavity of the shield unless the needle tip is exposed outside of the shield, which is undesirable from both the needle sterility and accidental needle stick safety standpoints. In order to enable the priming of the injection needle with a drug while the needle tip is completely covered and without the drug leaking inside the needle shield or its cavity, a priming-enabling component (PEC) for a 61 shielded needle may be included inside the needle shield. In some variations, the PEC could be a variation of the needle guide-tunnel described herein.
In one example, the priming-enabling component (PEC) comprises a narrow tunnel along its entire length (see, e.g., element 7014 in
Due to increased friction and resistance to the movement of the shield, such as when a slidable shield slides longitudinally along the injection needle, the limited length of the narrow segment or step of the needle tunnel, while the rest of the tunnel is wider, ensure that there is no excessive friction or resistance between the injection needle and the slidable shield movement.
Thus, the length of the narrow segment or step of the needle tunnel may be directly proportional to the resistance force of the slidable shield, whereas the ratio of the diameter of the resistance-controlling component of the tunnel versus the outer diameter of the injection drug conduit (e.g., injection needle) may be constant.
The diameter of the narrow (i.e., priming-enabling) portion or step in the tunnel can range from being slightly larger than the needle's outer diameter (OD) to slightly smaller, for example ±0.12 mm (0.005″) of the needle OD. 62
Examples of the injection needle OD relation to the diameter of the priming-enabling component (PEC) of the needle tunnel are as follow:
In one example, the diameter of the narrow (i.e., priming-controlling) step in the guide tunnel is the same as the diameter of the needle OD.
The reservoir is generally contained within the housing and may be configured in any suitable manner, so long as it is capable of delivering an active agent to the intraocular space using the actuation mechanisms described herein. The reservoir may hold any suitable drug or formulation, or combination of drugs or formulations to the intraocular space, e.g., the intravitreal space. It should be understood that the terms “drug” and “agent” are used interchangeably herein throughout. In one variation, the drug reservoir is silicone oil-free (lacks silicone oil or one of its derivatives) and is not internally covered or lubricated with silicone oil, its derivative or a modification thereof, which ensures that silicone oil does not get inside the eye causing floaters or intraocular pressure elevation. In another variation, the drug reservoir is free of any lubricant or sealant and is not internally covered or lubricated with any lubricating or sealing substance, which ensures that the said lubricating or sealing substance does not get inside the eye causing floaters or intraocular pressure elevation.
In some variations, the reservoir is made of a material that contains a cyclic olefin series resin, a cyclic olefin ethylene copolymer including commercially available products such as Zeonex® cyclo olefin polymer (ZEON Corporation, Tokyo, Japan) or Crystal Zenith® olefinic polymer (Daikyo Seiko, Ltd., Tokyo, Japan) and APEL™ cyclo olefin copolymer (COC) (Mitsui Chemicals, Inc., Tokyo, Japan), a cyclic olefin ethylene copolymer, a polyethylene terephthalate series resin, a polystyrene resin, a polybutylene terephthalate resin, and combinations thereof. In one variation, it may be beneficial to use a cyclic olefin series resin and a cyclic olefin ethylene copolymer that have a high transparency, a high heat resistance, and minimal to no chemical interaction with a pharmacological product such as a protein, a protein fragment, a polypeptide, or a chimeric molecule including an antibody, a receptor or a binding protein.
Exemplary agents may be selected from classes such as anti-inflammatories (e.g., steroidal and non-steroidal), anti-infectives (e.g., antibiotics, antifungals, antiparasitics, antivirals, and antiseptics), cholinergic antagonists and agonists, adrenergic antagonists and agonists, anti-glaucoma agents, neuroprotection agents, agents for cataract prevention or treatment, anti-oxidants, antihistamines, anti-platelet agents, anticoagulants, antithrombics, antiscarring agents, anti-proliferatives, anti-tumor agents, complement inhibitors, vitamins (e.g., vitamin B and derivatives thereof, vitamin A, depaxapenthenol, and retinoic acid), growth factors, agents to inhibit growth factors, gene therapy vectors, chemotherapy agents, protein kinase inhibitors, tyrosine kinase inhibitors, PEGF (pigment epithelial growth factor), small interfering RNAs, their analogs, derivatives, conjugates, and modifications thereof, and combinations thereof.
Exemplary complement inhibitors include, but are not limited to, antibodies or blocking peptides that inhibit at least one complement protein or fraction (e.g., anti-C5 agents, including antibodies such as anti-C5a and anti-C5b agents, and ARC1905; anti-C3 agents and antibodies, such as anti-C3 and anti-C3b, and other complement inhibitors, complement fraction inhibitors, or combinations thereof.
Particular agent classes that may be useful include without limitation, antineovascularization agents, anti-VEGF agents, anti-platelet derived growth factor agents, anti-64 placenta derived growth factor agents, anti-pigment epithelium derived growth factor agents, anti-PDGF pathway blocking agents (e.g., a PDGF-beta pathway blocking agent such as anti-PDGF-beta aptamers (e.g., Fovista™ anti-PDGF therapy), antibodies, blocking peptides or blocking small molecules), anti-PDGF-beta receptor agents (e.g., a PDGFR-beta blocking agent such as an aptamer, antibody, blocking peptide, or a blocking small molecule), anti-vascular permeability agents, protein kinase C inhibitors, EGF inhibitors, tyrosine kinase inhibitors, steroidal anti-inflammatories, nonsteroidal anti-inflammatories, anti-infectives, anti-allergens, cholinergic antagonists and agonists, adrenergic antagonists and agonists, anti-glaucoma agents, neuroprotection agents, agents for cataract prevention or treatment, anti-proliferatives, anti-tumor agents, complement inhibitors, vitamins, growth factors, agents to inhibit growth factors, gene therapy vectors, chemotherapy agents, protein kinase inhibitors, small interfering RNAs, aptamers, antibodies or antibody fragments, growth factor receptors and receptor fragments, analogs, derivatives, and modifications thereof, and combinations thereof. Further exemplary agents include an anti-complement fraction agent (e.g., an anti-C5 agent, anti-C5a agent, or anti-C3 agent) and aptamers, antibodies, and binding peptides thereof, and combinations thereof. In one variation, a combination of an anti-VEGF agent and an anti-PDGF agent is used.
Non-limiting, specific examples of drugs that may be used alone or as part of a combination drug therapy include Lucentis™ (ranibizumab), Avastin™ (bevacizumab), Fovista™ (anti-PDGF therapy), E10030 aptamer, Macugen™ (pegaptanib), anti-complement agents as described above, steroids, e.g., dexamethasone, dexamethasone sodium phosphate, triamcinolone, triamcinolone acetonide, and fluocinolone, taxol-like drugs, integrin or anti-integrin agents, vascular endothelial growth factor (VEGF) trap (aflibercept) (VEGF receptor fragments or analogs), anecortave acetate (Retaane), enzymes, proteases, hyaluronidase, plasmin, ocriplasmin, and limus family compounds, and combinations thereof. Non-limiting examples of members of the limus family of compounds include sirolimus (rapamycin) and its water soluble analog SDZ-RAD, tacrolimus, everolimus, pimecrolimus, and zotarolimus, as well as analogs, derivatives, conjugates, salts, and modifications thereof, and combinations thereof. In some instances it may be beneficial to employ a combination of agents. For example, it may be beneficial to combine two or more of the following for therapy: Lucentis™ (ranibizumab), Fovista™ (anti-PDGF therapy), Eylea® (aflibercept), an anti-PDGF agent, Macugen™, Jetrea™, a thrombolytic agent, and a steroid. In some instances it may be beneficial to combine 65 Lucentis™ (ranibizumab) and Fovista™ (or another anti-PDGF agent) combination, or Eylea® (aflibercept) and Fovista™ (or another anti-PDGF agent).
Topical anesthetic agents may also be included in the reservoirs. For example, lidocaine, proparacaine, prilocaine, tetracaine, betacaine, benzocaine, ELA-Max®, EMLA® (eutectic mixture of local anesthetics), and combinations thereof may be used.
Some variations of the injection devices described herein include a filter that filters the contents of the reservoir as it is delivered into the eye. For example, the filter may be used to remove infectious agents and enhance sterility of an active agent formulation before injection into the eye. Thus, inclusion of a filter into the device may be useful because the eye is an immune-privileged site, and introduction of even a small quantity of pathogens such as bacteria may cause sight-threatening intraocular infection (endophthalmitis). The filter may also be used to remove impurities, e.g., silicone droplets, from an active agent formulation prior to injection into the eye. This may be useful for intraocular drugs because a small impurity injected into a subject's eye may result in the subject seeing it as floater(s) that may be intractable, which significantly worsens the quality of vision.
In one variation, the filter pore size is between about 0.1 μm (microns) and about 10 μm (microns), between about 0.2 μm (microns) to about 5.0 μm (microns), or between about 0.2 μm (microns) and about 1.0 μm (microns) to facilitate filtration of bacterial pathogens, particulate matter or impurities such as silicone droplets from the outgoing drug being injected intraocularly. Thickness of the said may range from between about 50 μm (microns) to about 250 μm (microns), or from between about 10 μm (microns) to about 10000 μm (microns).
The filter may be made from any suitable non-reactive material, such as a low protein-binding material. Exemplary filter materials include without limitation, thermoplastic fluoropolymers such as PVDF (polyvinylidene fluoride); thermoplastic polymers such as polyethylene and polypropylene; mixed cellulose esters; nylons; polyesters; nitrocelluloses; acrylic polymers such as Versapor® acrylic copolymer; polyethersulfones such as found in Supor™ and Supor-R™ (Pall, Inc.) filters; a combination, a mixture, or a blend thereof.
The filter may be integrated with the device housing, the reservoir, the conduit, or any part of the device. In one variation, the filter is press-fit into a device lumen, for example into the lumen of a male-type luer, or a female-type hub, such as a drug conduit hub. In one variation, the filter is internal to the device. For example, the filter is configured to be inside the drug reservoir, or inside the conduit, or at the junction between reservoir and conduit. In another variation, filter is detachable or removable from the device. In one variation, the filter is located within the reservoir at its distal end, e.g., within the luer of a syringe. In another variation, the filter is located at the proximal end of the lumen of the conduit. The filter may also be placed at any location within and along the lumen of the drug delivery conduit, e.g., at its proximal end, in the middle, or at the distal end of the conduit.
In one example, the filter is integrated with the drug-loading conduit or device utilized to load a drug into the intraocular drug delivery devices described herein. For example, the filter is located inside the drug-loading conduit, or at or near the internal opening of the lumen of the drug-loading conduit. The filter may also be placed at any location within and along the lumen of the drug-loading conduit, e.g., at its proximal end, in the middle, or at the distal end of the conduit. For example, integrating a sterilizing filter within the drug-loading conduit may prevent microbial pathogens from room air from being introduced into the drug during the loading procedure.
In addition to removing infectious agents and/or impurities from the reservoir contents, the filter may function as a jet control mechanism that controls the force and limits the travel distance of the injected fluid as it exits the device and enters the eye. Other configurations of the jet control mechanism are also contemplated. The jet control mechanism may be generally configured to limit the maximum travel distance of the injected fluid to between about 5 mm and about 25 mm, between about 5 mm to about 20 mm, between about 5 mm and about 15 mm, or between about 5 mm to about 10 mm. In some instances, the maximum travel distance may be limited to less than about 25 mm, less than about 15 mm, less than about 10 mm, or less than about 5 mm. When a filter serves as the jet control mechanism, the pore size may range from about 0.05 μtm to about 10 μm, from about 0.1 μm to about 5 μm, or from about 0.2 μm to about 1 μm. Such a filter may also be placed within any portion of the device, e.g., near the device conduit. 67
The jet control mechanism may also include a fluid displacement control mechanism. The fluid displacement control mechanism may include a plunger rate control mechanism such as a mechanical interference, resistance component, or pneumatic control component that is configured to control the rate of plunger advancement within the reservoir of the device. The jet control mechanism may be beneficial because it improves the safety of intraocular drug injections, e.g., by minimizing the risk of serious adverse effects such as retinal detachment or other types of damage to intraocular structures by a forceful jet of fluid inside the eye.
It may also be advantageous to remove air from the reservoir contents before it is injected into the eye since the presence of intraocular air can result in unpleasant visual disturbances (“floaters”). The removal of air from a viscous composition, e.g., a viscous drug solution such as Lucentis® (ranibizumab injection), may be particularly beneficial. Thus, in some variations, the devices described herein may also include an air control mechanism for removing the amount of air introduced into the eye during intraocular drug administration. The air removal mechanism may be configured as a filter, a plurality of filters, a valve, a reservoir, or a combination of any of the foregoing. The air removal mechanism may be placed within any portion of the device, e.g., near the device conduit.
Some variations of the air control mechanism may include a hydrophobic filter or porous hydrophobic membrane that allows air through while retaining an aqueous drug solution. Exemplary materials that may be employed in the hydrophobic filters include without limitation, polytetrafluoroethylene (PTFE), Supor® R Membrane (Pall Corporation, Ann Arbor, Ml), Versapor® R Membrane (Pall Corporation, Ann Arbor, Ml), and other porous filter materials that have been coated or treated with a hydrophobic membrane such as Repel™ Acrylic Copolymer Membrane (Pall Corporation, Ann Arbor, Ml). The pore size of the air removal filters may range from about 0.05 μm to about 50 μm, from about 0.1 μm to about 10 μm, or from about 0.2 μm to about 5 μm.
Some variations of the air control mechanism may include a (e.g., proximal) extension of the drug conduit and its internal opening (or its holder or internal opening of the hub of the drug conduit) into the internal cavity of a syringe luer or drug reservoir (e.g., beyond the internal surface plane of the hub). Such proximal extension of the drug conduit and its internal opening 68 beyond the internal surface of its hub may provide an internal hub-luer seal (e.g., between the female-type hub, such as a disposable needle hub, and male-type luer, such as a syringe luer), where the seal prevents air and/or fluid in the drug solution or suspension from entering the cavity of the needle hub, but rather enables the air and/or fluid to pass directly from a drug reservoir into the drug conduit. For example, the said internal hub-luer seal may be generated by fit interference between the external surface of the proximal extension of the drug conduit or its internal hub continuation and the internal surface of the male-type luer of a drug reservoir, such as a syringe luer.
The internal hub-luer seal may be the only seal or a secondary seal between the drug conduit's hub and drug reservoir's luer, for example in addition to the conventional seal between the external surface of the syringe luer and the internal surface of the needle hub cavity.
In one example, the proximal, internal extension of the drug conduit may have a conical or pyramidal shape with slanted or sloped external walls in order to enable the creation of a tight seal as it enters the distal opening of a syringe luer or a drug reservoir. It may also enable the creation of an air- and/or water-tight seal between the drug conduit and a variety of different syringe luers having different internal diameter. In one variation, the external diameter of the distal end of the conduit proximal extension is different than that of its proximal end. For example, the distal end diameter is larger than the proximal end external diameter of the conduit's extension. For example, the angle of the sloped external walls of the proximal drug conduit extension may be between 1 degree and 45 degrees, or between 3 degrees and 30 degrees, or between 5 degrees and 15 degrees.
Given that the internal diameter angle of the standard syringe luer is 1.8 degrees, a larger angle of the sloped conduit extension walls may be needed to enable an internal luer seal. While the injection device is being attached to a drug reservoir (i.e., a luer syringe), the sequence of steps may be such that the syringe luer is locked with the injection device hub followed by the creation of an internal luer seal. Thus, a certain angle of the sloped walls of the conduit extension may be required for the internal seal to form. Creation of an internal luer seal may also depend on the inside diameter of the syringe luer and the length of the luer-lock component.
The internal hub-luer seal may prevent air bubbles from entering the drug conduit and being injected into the eye causing bothersome “floaters”. For example, air bubbles passing by the drug conduit's internal opening during its priming may pass into the proximal part of the hub and get trapped there, or continue to pass for example through a filter (e.g., a hydrophobic filter) out of the hub. In addition, proximally extended drug conduit's internal opening beyond the internal plane of its hub may prevent potential clogging of the drug conduit by the glue used to attach the needle to the hub. This way, the needle shaft rather than its proximal open end will be glued into the hub, reducing the chance of glue clogging the needle or interacting with the drug.
In one variation, the drug conduit may comprise more than one internal and/or external diameter. For example, the proximal part of the drug conduit, some or all of which may penetrate the eye wall, may have a small internal and/or external diameter (e.g., 33 gauge, or within the 30 to 33 gauge range) whereas its proximal portion may have a larger internal and/or external diameter (e.g., 30 gauge, or within the 25 to 31 gauge range). In one example, the proximal portion of the drug conduit comprises a narrower, 31 gauge or 32 gauge or 33 gauge needle, whereas the proximal portion of the drug conduit comprises a wider, 25 to 30 gauge needle.
In some variations, the drug conduit comprises a needle with at least a portion being tapered (e.g., internal, external, or both internal/external diameter being narrower towards its distal end). In one variation, the drug conduit comprises a needle with at least two portions, or the entire needle being tapered (e.g., narrower internal, external or both internal/external diameter towards its distal end). This design allows for the proximal portion of the drug conduit (that does not penetrate the eye wall or enter an eye cavity) to have wider diameter therefore reducing the overall resistance to the drug flow while maintaining patient comfort due to the small needle gauge coming in contact with the eye. Such drug conduit having reduced resistance to drug flow is particularly important when using large molecular size drugs (such as proteins and other biopharmaceuticals), small-gauge needles (such as 30 to 33 gauge needles), or using proximally extended and elongated needles described herein.
In one variation, the proximal extension of the drug conduit or a tunnel connected to the drug conduit into the female-type luer connector or hub of the device (e.g. internal luer 70 connector), may be able to puncture a membrane, a stopper, or a cap covering the distal entrance into the drug reservoir cavity, for example a syringe luer. This may be used with loadable and prefilled drug reservoirs or syringes, and may ensure the air-free drug injection. Such internal luer connector may also minimize the dead volume of a device-drug reservoir system, and enhance sterility. In one example, the internal luer connector (e.g., as shown in
In some variations, there is a two-step connection between the device and a drug reservoir. In one example, the drug injector comprising such an internal luer connector may be removably attached to a drug-prefilled syringe or container, but with a membrane seal intact preventing drug exposure to air (e.g. enabling a first-step connection). When the device is ready to be used, the internal luer connector is advanced further proximally without removing the device to enable its penetration through the membrane seal and provide direct communication between the internal opening of the drug conduit and the drug (e.g. enabling a second-step connection). Such proximal advancement of the internal luer connector through the membrane or seal covering a drug reservoir distal entrance may be achieved by turning the luer lock mechanism or a similar luer connection mechanism, for example, a quarter or half turn. In another example, the proximal advancement of the internal luer connector to break the drug seal may be achieved by snapping the device hub further onto the external luer connector.
The devices described herein may further include a terminal sterilization mechanism that includes a filter for removing infectious agents and particulate matter (as previously described) alone, or in combination with an air removal mechanism, e.g., an air removal filter. The terminal sterilization mechanism generally removes bacteria and particles from the drug solution as it exits the device and enters the eye. The inclusion of a terminal sterilization mechanism may help to minimize the risk of intraocular infection or inflammation such as endophthalmitis or sterile uveitis. The terminal sterilization mechanism may be configured as a filter comprising a hydrophilic membrane that is placed within any portion of the device, e.g., near the device conduit. The pore size of such a filter may range from about 0.05 μm to about 10 71 μm, from about 0.1 μm to about 5 μm, or from about 0.2 μm to about 1 μm. In some variations, the filter is a non-protein binding or low protein-binding filter. Here exemplary hydrophilic filter materials include without limitation, thermoplastic fluoropolymers such as polyvinylidene fluoride (PVDF), mixed cellulose esters, nylons, polyesters, nitrocelluloses, and combinations, mixtures, or blends thereof. In one variation, the hydrophilic filter is treated with an oleophobic material to repel oil. The oleophobic material may be silicone oil.
It is understood that the injection devices described herein may include an air removal mechanism, a terminal sterilization mechanism, a jet control mechanism, or any combination thereof. When a plurality of filters are employed (e.g., in a filter assembly), both hydrophobic and hydrophilic filters may be used. In some instances, non-protein binding or low protein-binding filters are used. For example, as shown in
An air removal mechanism may be particularly beneficial when an air bubble in a drug solution or suspension covers a substantial amount of the surface area of a poorly gas-permeable membrane such as a hydrophilic membrane. The air bubble generally increases resistance to flow of the drug composition, in turn decreasing its flow rate, to thereby cause an airlock. In other instances, e.g., when a fine pore hydrophilic membrane with a small surface area is utilized (that is poorly permeable to air), small air bubbles can aggregate on its surface and fuse into larger air bubbles that may eventually cause an airlock. Here the hydrophilic filter membrane may have a surface area less than about 25 mm2, or less than about 9 mm2, or less than about 4 mm2 • In another example, the effective filtration surface area of a hydrophilic membrane may be between about 0.1 mm2 and 100 mm2, or between about 1 mm2 and 25 mm2. 72
As a solution to the problem described above, a drug delivery device (e.g., an injector device) may be provided that comprises a gas-resistance component (e.g., a hydrophilic filter) and a vent (e.g., a hydrophobic filter). A hydrophilic filter membrane may increase the resistance to air or gas flow and prevent it from passing through a drug conduit while also diverting it through a hydrophobic filter vent and out of the device to facilitate air or gas removal from the drug composition. The vent and gas-resistance resistance components may be adjacent to each other. The vent and gas-resistance components may also be integrally formed with the needle hub or provided as separate, attachable/detachable components. The gas-resistance component may be at least partially air-impermeable under any condition, or at least partially air-impermeable under certain conditions, e.g., when wetted. The gas-resistance component may prevent air in the drug composition from entering a drug conduit. The vent may provide an anti-air lock mechanism, or a gas (air)-removal mechanism. For example, the vent may comprise an air-release valve or a hydrophobic membrane.
In some variations, the gas-resistance component may comprise a sterilization filter. For example, the gas-resistance component may include a hydrophilic membrane, such as a hydrophilic membrane filter that produces filter-sterilization of the drug composition as it passes through it and is ejected from the device. The hydrophilic filter membrane may be flat, convex, or concave in order to facilitate aggregation and fusion of small air bubbles into larger ones, to help with their removal by the air-removal component. In other variations, the pore size of the hydrophilic membrane may be small, making it less permeable to air and causing small air bubbles to aggregate on its surface and fuse into larger bubbles. The larger bubbles may enhance their removal by the air-removal component. The gas-resistance component may comprise a hydrophilic membrane with a pore size ranging between about 0.02 μm and about 5 μm, or about 0.1 μm and about 1 μm. Some variations of the hydrophilic membrane may have a pore size of about 0.2 μm.
In yet further variations, the drug delivery device may include an oil-removal component. In one example, the oil-removal component is part of, e.g., removable attached to, or integrated with, a terminal sterilization component. The oil-removal component may be a combination of a hydrophilic/oleophobic filter and at least one hydrophobic/oleophilic filter 73 adjacent to or in close proximity to the hydrophilic filter. Oleophobic and oleophilic coatings may also be used to impart oleophobic or oleophilic properties to the filters.
Other filter structures and filter assembly configurations are also contemplated. For example, in some instances the filter may be structured to include a hydrophilic center and a hydrophobic periphery, or vice versa. These filters may have any suitable shape and geometry, e.g., the filters may be shaped to be flat, concave, convex, or discoid. In some variations, the filter assembly comprises filters of different types, e.g., a first filter and a second filter, where one is hydrophilic and the other is hydrophobic. When dual filters are employed, the filters may be arranged so that they are adjacent one another. The filters may be positioned so that a certain angle is formed between their surfaces, e.g., an angle between about 45 degrees and about 135 degrees, or between about 70 degrees and about 110 degrees. In some variations, the angle between the hydrophilic and hydrophobic filters may be about 90 degrees. For example, a 90 degree angle may be formed by placing a hydrophilic filter in the needle hub near the proximal end of the needle lumen, and a hydrophobic filter(s) in the wall of the needle hub. The filter assembly may include more than two filters and/or more than two types of filters in certain instances.
Referring to
Alternatively, as shown in
In an integrated device, as shown in
The reservoirs and devices described here may be suitable for intraocular administration of a very small volume of a solution, suspension, gel or semi-solid substance. For example, a volume between about 1 μl and about 200 μl, or between about 10 μl and about 150 μl, or between about 20 μl and about 100 μl may be delivered. To that end, the device will generally have a very small “dead space,” which enables intraocular administration of very small volumes.
The volume of a solution, suspension, gel or semi-solid substance may be even smaller when injected into the eyes of children, infants, or premature infants, where the intravitreal volume may be as small as about 4.0 ml. Thus, an injection device as described herein that is configured to inject such a small volume may be beneficial to use when treating retinopathy of prematurity or other diseases of the eye that affect these populations. Such a device may deliver a micro-volume of drug, e.g., a volume less than about 50 μl. In some variations, the microvolume injector may deliver between about 5.0 μl to about 30 μl of drug. In other variations, the micro-volume injector may deliver between about 10 μl and about 25 μl of drug.
The housing of the micro-volume injector may have an outside diameter (OD) that is substantially the same, or the same, as that of a larger volume device. For example, the OD may range from about 3.0 mm to about 11 mm, from about 5.0 mm to about 10 mm, or from about 6.0 mm to about 9.5 mm. However, the drug reservoir within the housing will generally define an inner diameter (ID) that may be smaller. For example, the ID may range from about 1.0 mm 75 to about 5.0 mm, from about 1.5 mm to 5.0 mm, or from about 2.0 mm and 3.0 mm, in order to precisely measure the a small amount of a drug solution.
In some instances, the smaller ID may be achieved by thickening the wall of the drug reservoir to measure, e.g., between about 1.0 mm and 3.0 mm, or between about 1.2 mm and about 2 mm. In another example, this could be achieved by expanding the OD within the grip/handle area only, for example, by adding an external handle, grip, or expander to increase the outer diameter (OD) of an area to range between about 3.0 mm and about 11.0 mm, or between about 5.0 mm and about 10 mm, or between about 6.0 mm and about 9.5 mm, while keeping the ID of the drug reservoir the same small size, for example, between about 1.0 mm and about 5.0 mm, or between about 1.5 mm and 5.0 mm, or between about 2.0 mm and 3.0 mm, throughout the entire or partial axial length of the drug reservoir. Thus, the wall thickness of the drug compartment may be thin (e.g., between about 0.7 mm and about 1.2 mm, or between about 0.8 mm and about 1.2 mm) in front of the handle/grip area in order to directly visualize the drug within the drug reservoir during drug loading, as well as to ensure complete air removal and to facilitate the priming of the device and drug conduit (e.g. needle).
In some variations, the internal radius of the reservoir of the injection device is configured to be proportional to the drug injection volume. Here the plunger travel distance (L) within drug reservoir is constant may equal 12.7 mm(+/−5 mm). Thus, for an incompressible fluid (e.g., a drug solution or suspension), the square of the internal drug reservoir radius is proportional to the drug injection volume. That is: Injection volume=π r2L and L=Injection volume/πr2L; where L is the plunger travel distance and r is the internal radius of the drug reservoir.
Using these formulas, the plunger travel distance and internal radius of the reservoir can be tailored to optimize delivery of small injection volumes. For example: For an injection volume of 0.05 ml and a length (L) of 12.7 mm, the radius will be 1.12 mm; 76 For an injection volume of 0.05 ml and a length (L) of 7.7 mm, the radius will be 1.44 mm; For an injection volume of 0.05 ml (L) and a length of 17.7 mm, the radius will be 0.95 mm; For an injection volume of 0.03 ml and a length (L) of 12.7 mm, the radius will be 0.87 mm; For an injection volume of 0.03 ml and a length of 7.7 mm, the radius will be 1.11 mm; and For an injection volume of 0.03 ml and a length of 17.7 mm, the radius will be 0.74.
In one variation, and as shown in
An expanded, cross-sectional view of the housing tip (5012) is shown in
The device reservoirs may be pre-loaded during the manufacturing process or loaded manually before the intraocular injection, as further described below. Drug Loaders
Front loading of an injection device when the drug is loaded through the injection needle generally dulls the needle tip and removes at least some of the lubricant coating from the needle making it more difficult and uncomfortable for the needle to penetrate the target tissue. There is also a higher risk of contaminating the injection needle while manipulating it with a drug container. Back loading, for example through the plunger, often leads to wasting a significant amount of the drug, for example, more than 0.05-0.1 mL, which is undesirable with expensive agents, as well as when smaller drug volumes are used, as is typically the case for intravitreal injections. Here total volumes in the range of 0.05-0.1 ml are generally used. When a detachable needle is used, drug may be lost in the syringe luer and needle hub when the loading needle is exchanged with an injection needle, and contamination of the sterile drug conduit may occur. Thus, it would be beneficial to have a front or side-loading mechanism that allows for direct loading of the drug into drug reservoir without passing the drug through the tip of the drug conduit, exchanging or detaching the drug conduit, or losing a significant volume of the drug during the loading process.
In view of the above, when a drug or formulation is to be loaded into the reservoir of the devices described herein prior to intraocular injection, a loading member may be employed. The loading member may be removably attached to the distal end of the housing. For example, the loading member may function as a loading dock that quantitatively controls the volume of a liquid, semi-liquid, gelatinous, or suspension drug that is to be loaded into the device. For example, the loading member may comprise a dial mechanism (21) that allows the operator to preset a particular volume of a drug to be loaded into the device (
As shown in
In one variation, the dock mechanism comprises a needle or a sharp cannula that has openings or fenestrations (39) at its base. The said openings or fenestrations are positioned immediately adjacent to the internal aspect of the vial stopper when the loading dock penetrates into the drug vial while in the desired loading position, which in turn enables airless drug loading into the device as well as complete drug removal from the storage container. Airless drug loading may be beneficial because it may prevent the patient from seeing small intraocular air bubbles or “floaters.” Complete drug removal is also beneficial given that small drug volumes and expensive medications are typically used.
Some variations of the loading mechanism comprise a cannula or needle. The length of such a needle or cannula is sufficient to penetrate into the lumen of the drug reservoir. In one example, the length of the loading needle or cannula is such that its tip reaches the opposite wall of the drug lumen when it is inserted perpendicularly to the device wall, in order to minimize the amount of air bubbles formed during drug loading. For example, the length of the loading needle or cannula is between about 0.1 mm and about 5 mm. 79
In other variations, for example, when the devices have a flat side surface (
In further variations, as shown in
Access port (144) may comprise a seal or a plug configured to seal the reservoir against air or fluid leak, and/or external bacterial contamination and may be made from any suitable material, e.g., silicone, rubber, or any soft thermoplastic polymer such as, but not limited to, 80 polyurethane, Kraton™ styrenic block copolymers consisting of polystyrene blocks and rubber blocks, polyethylene, polypropylene, polyvinyl chloride, or combinations thereof that allows sealable penetration by a sharp conduit.
In some variations, the access port stopper or seal may comprise a fully or partially encircling sleeve. Here the sleeve may also serve as a finger grip or a holder. In another variation, and as shown in
One or multiple membranes (148) may also be provided, e.g., in the ocular contact surface (108) to seal the internal compartment of the housing against air leak and/or external bacterial contamination. For example, the thickness of the membrane or the combined plurality of membranes may range from about 0.025 mm to about 5.0 mm, or range from about 0.1 mm to about 1 mm. One or multiple small apertures (150) may also be included in the wall of the housing (102) to help control air outflow from the housing (102). The number and diameter of the apertures (150) may be varied to control the rate of (needle assembly and) needle deployment.
In some variations, e.g., when a pneumatic actuation mechanism is used, drug loading may be controlled by a drug-loading piston. For example, as shown in
Some variations of the drug loading devices include a filter that filters the contents of the drug container as it is delivered into the reservoir. For example, the filter may be used to remove infectious agents and enhance sterility of an active agent formulation before delivery into the reservoir. Thus, inclusion of a filter into the drug loader may be useful because the eye is an immune-privileged site, and introduction of even a small quantity of pathogens such as bacteria may cause sight-threatening intraocular infection (endophthalmitis). The filter may also be used to remove impurities, e.g., silicone droplets, from an active agent formulation as it is transferred to the reservoir and prior to injection into the eye. This may be useful for intraocular drugs because a small impurity injected into a subject's eye may result in the subject seeing it as floater(s) that may be intractable, which significantly worsens the quality of vision.
In one variation, the filter pore size is between about 0.2 μm (microns) and about 10 μm (microns) to facilitate filtration of bacterial pathogens from the outgoing drug being injected intraocularly. In another variation, the filter pore size is between about 0.1 μm (microns) and about 500 μm (microns) to facilitate filtration of particulate matter or impurities such as silicone droplets from the outgoing drug being injected intraocularly. In yet a further variation, the filter pore size is between about 0.2 μm (microns) to about 4.0 μm (microns). Thickness of the said filter may range from between about 50 μm (microns) to about 250 μm (microns), or from between about 10 μm (microns) to about 10000 μm (microns).
The filter may be made from any suitable non-reactive material, such as a low protein-binding material. Exemplary filter materials include without limitation, thermoplastic fluoropolymers such as PVDF (polyvinylidene fluoride); mixed cellulose esters; nylons; polyesters; nitrocelluloses; acrylic polymers such as Versapor® acrylic copolymer; polyethersulfones such as found in Supor™ filters; a combination, a mixture, or a blend thereof.
The filter may be integrated with the drug loading device housing, the reservoir, a conduit, or any suitable part of the device. In another variation, filter is detachable or removable from the device. In one variation, the filter is located within the reservoir at its distal end. In another variation, the filter is located at the proximal end of the lumen of the conduit. The filter may also be placed at any suitable location within and along the lumen of the conduit, e.g., at its proximal end, in the middle, or at the distal end of the conduit. 82 Actuation Mechanisms
The devices described here generally include an actuation mechanism within the housing that deploys the conduit from the housing and enables the delivery of drug from the device into the intraocular space. In other variations, the conduit is deployed by an actuation mechanism contained within a separate cartridge that can be removably attached to the device housing, e.g., using snap-fit or other interlocking elements. The actuation mechanisms may have any suitable configuration, so long as they provide for accurate, atraumatic, and controlled delivery of drug into the intraocular space. For example, the actuation mechanisms may deliver a drug or formulation into the eye by way of intraocular injection at a rate ranging from about 10/sec to about 1 ml/sec, from about 5 μl/sec to about 200 μl/sec, or from about 10 μl/sec to about 100 μl/sec. The actuation mechanisms may generally provide a force of needle deployment that is strong enough to penetrate the eye wall comprising the conjunctiva, sclera and the pars plana region of the ciliary body, but less than that causing damage to the intraocular structures due to high velocity impact. This force depends on several physical factors, including but not limited to, the needle gauge utilized, the speed/rate of needle deployment at the point of contact between the needle tip and the eye wall which in turn determines the impact force. An exemplary range of force that may be generated by the actuation mechanisms is about 0.1 N (Newton) to about 1.0 N (Newton). The velocity of needle deployment may also range between about 0.05 seconds and about 5 seconds.
In some variations, the actuation mechanism is a single-spring mechanism. In other variations, the actuation mechanism is a two-spring mechanism. In further variations, the actuation mechanism is pneumatic, e.g., employing negative pressure such as vacuum, or a positive pressure driven mechanism. In further variations, the actuation mechanism is driven magnetically or electrically, e.g., by a piezo-electric or magnetic rail mechanism. These types of actuation mechanisms may be configured to allow independent control of the rate and force of drug injection (controlled, e.g., by the first spring member in the two-spring variation), and the rate and force of the dispensing member deployment (controlled, e.g., by the second spring member in the two-spring variation). Exemplary two-spring mechanisms are shown in
In
Activation of the first spring (114) of the actuation mechanism by activating the trigger deploys the needle (124) into the intraocular space, i.e., it moves the needle (124) from its first non-deployed state (
Activation of the first spring (114) will typically result in activation of the second spring (116) to deliver drug out of the device and into the intraocular space. For example, as shown in
A two-spring actuation mechanism, as shown in
In some variations, a single-spring actuation mechanism is employed, as shown in
A pneumatic actuation mechanism may also be employed. In one variation, as depicted in
As previously stated, a trigger may be coupled to the housing and configured to activate the actuation mechanism. In one variation, the trigger is located on the side of the device housing proximate the device tip at the ocular interface surface (e.g., the distance between the trigger and device tip may range between 5 mm to 50 mm, between 10 mm to 25 mm, or between 15 mm to 20 mm), so that the trigger can be activated by a fingertip while the device is positioned over the desired ocular surface site with the fingers on the same hand. In another variation, the trigger is located on the side of the device housing at 90 degrees to the measuring component, so that when the ocular contact surface is placed on the eye surface perpendicular to the limbus, the trigger can be activated with the tip of the second or third finger of the same hand that positions the device on the ocular surface.
Some variations of the device may include a control lever for initiating plunger movement. In these instances, the control lever may actuate the plunger in a mechanical manner, e.g., by spring-actuation, similar to that described above. In other variations, actuation of the plunger may occur through a combination of mechanical and manual features. For example, the initiation of plunger movement may be aided by a manual force applied onto the control lever, while a spring-actuated mechanism for generating a mechanical force is also employed to move the plunger forward inside the device barrel to inject drug. In instances where the control lever is connected to the plunger, the initiation of plunger movement and drug injection is controlled by the manual component, whereas the rate of fluid injection is controlled by the mechanical force. Here a reduced manual force may be applied to the plunger due to its combination with a codirectional mechanical force, thus facilitating the stability of device positioning on the ocular surface at a precise injection site.
The control lever may be placed between 10 mm and 50 mm from the tip of the device that interfaces with the eye surface, or between 20 mm and 40 mm from the tip of the device. 87 Positioning of the control lever in this manner may enable atraumatic and precise operation of the device with one hand.
As illustrated in
The dynamic sleeve may be slidably advanced or retracted manually by a fine mobility control mechanism, also referred to as a mobility control mechanism. In these instances, the dynamic sleeve may comprise a high-traction surface located on the outer surface of the sleeve, which may aid movement of the sleeve with a fingertip. In one variation, the high-traction surface may be engraved or contain markings with a serrated pattern. In other variations, as shown in
Some variations of the devices described herein include a grip having a retraction slot or channel that works in combination with the dynamic resistance component to inject drug into the eye. Referring to
When grips are employed, the devices may also include a locking mechanism. In one variation, when the end point of the sleeve retraction and needle exposure/deployment is reached, the wide portion of the sleeve slot is aligned with the wide portion of a grip slot and with an opening in the housing and an opening in the plunger shaft, allowing the platform base to be inserted into the plunger shaft to lock it relative to the platform that become an actuation lever for manual drug injection. The narrow part of the base enters the narrow part of the sleeve slot, which unlocks the platform relative to the sleeve allowing its movement towards device tip. In another variation, when the platform base reaches the end point of the retraction slot, it may be depressed into an opening in the plunger shaft and becomes a locking pin to connect the platform and the plunger. When it is depressed, its narrow portion enters the keyhole-shaped slot in the sleeve, and becomes movable within the slot moving towards the tip of the sleeve (unlocks the platform base and sleeve).
The mobility control mechanism may be beneficial when the user desires to control the amount of pressure exerted by the device tip on the eye surface in order to deploy the needle during its intraocular penetration. With a mobility control mechanism, the user may use a fingertip to either reduce or increase counter-forces that regulate the sleeve movement and needle exposure. 89
For example, if the user exerts the pulling force onto the said high-traction surface (that is pulling the high-traction surface of the sleeve away from the device tip), this movement may facilitate needle exposure and reduce the amount of pressure force (down to 0 Newton) needed to be applied to the eye wall in order to slide the sleeve back and expose the needle. In another variation, if the user exerts a pushing force (that is pushing the high-traction surface of the sleeve towards the device tip), this movement may counteract and impedes needle exposure, which may allow the device tip to apply increased pressure to the eye wall prior to the initiation of sleeve movement and needle exposure.
In use, the platform or pad may be slid with a second or third finger. Again, this allows the injector to manually modulate the sleeve resistance and movement along the device tip. For example, by pushing the pad and thus the sleeve forward with a fingertip, the injector provides some resistance at the beginning of the procedure when the device tip is being positioned on the eye surface (and the needle needs to remain completely covered). Then the injector would release his/her fingertip from the sleeve pad to enable needle deployment and its transscleral penetration. Some variations of the device may also include a step or a ring-shaped ridge at the end of the sleeve path, so that after the sleeve is pulled back past this step, it would automatically trigger spring-actuated plunger movement. The fingertip pad could be used to pull the sleeve back past the said step at the end of needle deployment in order to actuate the plunger movement and drug injection.
When a platform or pad is employed, it may reduce the amount of pressure the device exerts on the eyeball before the sleeve begins to move to expose the needle, and thus, allow customization of the amount of applied pressure from patient to patient.
In another aspect, the dynamic sleeve may provide gradual needle exposure as it penetrates through the eye wall so that the needle is exposed 1 mm or less when it meets most resistance at the eye surf ace. Here the rest of the needle is located inside the sleeve with at least its most distal unexposed point or a longer segment being protected inside the narrow exit orifice or canal. Such sleeve design may minimize the risk of needle bending compared to the conventional syringe with a long exposed needle. This design may enable the utilization of smaller a gauge needle without increased risk of it being bent as it penetrated through the eye 90 wall. The smaller needle gauge may render it more comfortable and less traumatic during its intraocular penetration.
Some variations of the devices described here may comprise an endpoint shock absorber. The endpoint shock absorber may be a component that cushions the eye against the force transmitted by the dynamic sleeve and the needle when they come to an abrupt stop. The transmitted force wave may be harmful for the delicate structures inside the eye such as the lens, retina and the choroidal vasculature. Inclusion of an endpoint shock absorber may allow the needle to come to a soft and gradual stop at the end of its deployment path when it is fully extended through the eye wall into the intraocular cavity. In one variation, the shock absorber is provided as a tapered surface at the distal end or distal portion of the dynamic sleeve. In another variation, the shock absorber is a soft sleeve located at the base of the drug conduit (such as at the hub of an injection needle). Here the soft sleeve may be configured to contact the tip of the device when the needle is fully deployed. In yet another variation, the shock absorber is the soft tip of the device, where the soft tip is configured to contact the hub of the needle when the needle is fully deployed. Exemplary materials suitable to make the endpoint shock absorbers include without limitation, methylmethacrylate (MMA); polymethylmethacrylate (PMMA); polyethylmethacrylate (PEM) and other acrylic-based polymers; polyolefins such as polypropylene and polyethylene, vinyl acetates, polyvinylchlorides, polyurethanes, polyvinylpyrollidones, 2-pyrrolidones, polyacrylonitrile butadiene, polycarbonates, polyamides, fluoropolymers such as polytetrafluoroethylene (e.g., TEFLON™ polymer); polystyrenes; styrene acrylonitriles; cellulose acetate; acrylonitrile butadiene styrene; polymethylpentene; polysulfones; polyesters; polyimides; natural rubber; polyisobutylene rubber; polymethylstyrene; silicone; and derivatives, copolymers and blends thereof.
The devices described herein may also include a visual feedback mechanism or a needle deployment indicator configured to allow the operator to precisely determine when the needle has been deployed to the desired extent, and to safely initiate drug injection. Furthermore, during the needle deployment process, the eyes of the operator should be pointed at or near the device tip-eye interface. Thus, it would be beneficial for the visual feedback mechanism to be located in close proximity to the device tip-eye interface, so as not to distract the operator from closely monitoring the device position during the entire intraocular drug 91 delivery procedure. With such a configuration, the operator does not have to take his/her eyes off of the device-ocular interface during the entire injection procedure, minimizing the risk of accidental trauma during unexpected movement of the eye or head of the subject. In some variations, the visual feedback mechanism may be coupled to a mechanical stopper at the endpoint of the needle deployment process. Here the visual feedback mechanism may be configured as an elongated measuring tip band, where the tip comes up to a stop against the needle base or hub, which determines the end-point of needle deployment when the sleeve has been fully retracted. In one variation, the needle base and/or the distal end of the needle hub is colored in a high-visibility dye, such as black, that could be directly visualized through a transparent or translucent material of the slidable shield. Another example of the visual feedback mechanism is a band or a spacer placed on the needle base, so that the band comes up to a stop against the inside surface of the tip, which determines the end-point of needle deployment when the sleeve has been fully retracted.
An exemplary injection device is shown in
In
The injection device of
Referring to
Methods for using the intraocular drug delivery devices are also described herein. In general, the methods include the steps of positioning an ocular contact surface of the device on the surface of an eye, applying pressure against the surface of the eye at a target injection site using the ocular contact surface, and delivering an active agent from the reservoir of the device into the eye by activating an actuation mechanism. The steps of positioning, applying, and delivering are typically completed with one hand.
The methods may also include placing an ocular contact surface of an injection device against the eye wall, generating variable resistance to conduit advancement as the conduit is 94 deployed through the eye wall, removing air from the composition before the composition is delivered into the eye by passing the composition through an air removal mechanism, and injecting the composition into the eye.
In some instances, the method may include coupling an injector attachment to a syringe body, the injector attachment comprising a variable resistance component, an air removal mechanism, an ocular contact surface, and a needle, and the syringe body having a proximal end and a distal end, and a reservoir for containing a composition therein; placing the ocular contact surface of the injector attachment against the eye wall; generating variable resistance to needle advancement as the needle is deployed through the eye wall; removing air from the composition before the composition is delivered into the eye by passing the composition through the air removal mechanism; and injecting the composition into the eye.
In addition to removing air, the method may further comprise the step of removing bacteria or particulates from the composition before the composition is delivered into the eye, the step of limiting the injection force of the composition, and/or the step of limiting the distance the composition travels in the eye when the composition is injected. When the distance of composition travel in the eye is limited, the distance may be limited to between about 5 mm and about 25 mm, between about 5 mm to about 20 mm, between about 5 mm and about 15 mm, or between about 5 mm to about 10 mm. As previously stated, the removal of air from the composition before it is delivered into the eye may be particularly beneficial when a viscous composition, e.g., a composition comprising ranibizumab, is injected.
The application of pressure against the surface of the eye using the ocular contact surface may also be used to generate an intraocular pressure ranging between 15 mm Hg to 120 mm Hg, between 20 mm Hg to 90 mm Hg, or between 25 mm Hg to 60 mm Hg. As previously stated, the generation of intraocular pressure before deployment of the dispensing member (conduit) may reduce scleral pliability, which in turn may facilitate the penetration of the conduit through the sclera, decrease any unpleasant sensation on the eye surface during an injection procedure, and/or prevent backlash of the device. Intraocular pressure control may be generated or maintained manually or automatically using pressure relief valves, pressure sensors, pressure 95 accumulators, pressure sensors, or components such as slidable caps having locking mechanisms and/or ridges as previously described.
Use of the devices according to the described methods may reduce pain associated with needle penetration through the various covers of the eye wall such as the conjunctiva that is richly innervated with pain nerve endings. The anesthetic effect at the injection site during an intraocular injection procedure may be provided by applying mechanical pressure on the conjunctiva and the eye wall over the injection site before and/or during the needle injection. The application of mechanical pressure to the eye wall may also transiently increase intraocular pressure and increase firmness of the eye wall (and decrease its elasticity), thereby facilitating needle penetration through the sclera. Furthermore, the application of mechanical pressure to the eye wall may displace intraocular fluid within the eye to create a potential space for the drug injected by the device.
The devices may be used to treat any suitable ocular condition. Exemplary ocular conditions include without limitation, any type of retinal or macular edema as well as diseases associated with retinal or macular edema, e.g., age-related macular degeneration, diabetic macular edema, cystoid macular edema, and post-operative macular edema; retinal vascular occlusive diseases such as CRVO (central retinal vein occlusion), BRVO (branch retinal vein occlusion), CRAO (central retinal artery occlusion), BRAO (branch retinal artery occlusion), and ROP (retinopathy of prematurity), neovascular glaucoma; uveitis; central serous chorioretinopathy; and diabetic retinopathy.
When dexamethasone sodium phosphate solution is used to treat an ocular condition, the dose of dexamethasone sodium phosphate that may be administered into the eye by each individual injection device may range between about 0.05 mg and about 5.0 mg, between about 0.1 mg and about 2.0 mg, or between about 0.4 mg and about 1.2 mg.
In some variations, a topical anesthetic agent is applied on the ocular surface before placement of the device on the eye. Any suitable topical anesthetic agent may be used. Exemplary topical anesthetic agents include without limitation, lidocaine, proparacaine, prilocaine, tetracaine, betacaine, benzocaine, bupivacaine, ELA-Max®, EMLA® (eutectic mixture of local anesthetics), and combinations thereof. In one variation, the topical anesthetic 96 agent comprises lidocaine. When lidocaine is used, it may be provided in a concentration raging from about 1% to about 10%, from about 1.5% to about 7%, or from about 2% to about 5%. In another variation, the topical anesthetic agent is mixed with phenylephrine or another agent that potentiates or/and prolongs the anesthetic effect of the pharmaceutical formulation. The topical anesthetic agent may be provided in any suitable form. For example, it may be provided as a solution, gel, ointment, etc.
An antiseptic agent may also be applied on the ocular surface before placement of the device on the eye. An antiseptic agent may also be applied to the device tip before placement of the device on the eye. Examples of suitable antiseptic agents include, but are not limited to, iodine, iodine-containing combinations, povidone-iodine (Betadine®), chlorhexidine, soap, antibiotics, salts and derivatives thereof, and combinations thereof. The antiseptic agent may or may not be applied in combination with a topical anesthetic agent. When the antiseptic comprises povidone-iodine (Betadine®), the concentration of povidone-iodine may range from about 1% to about 10%, from about 2.5% to about 7.5%, or from about 4% to about 6%.
During the drug delivery process, the devices described here may be configured so that the injection needle enters the eye at the right angle that is perpendicular to the eye wall (sclera). In other instances, the device may be configured so that the injection needle enters through the cornea into the anterior chamber of the eye parallel to the iris plane.
Systems and kits that include the intraocular drug delivery devices disclosed herein are also provided. The kits may include one or more integrated drug delivery devices, one or more injection devices, one or more conventional syringes, and/or one or more removably couplable injector attachments. The devices may be preloaded with an active agent. When a plurality of preloaded devices are included, they may be separately packaged and contain the same active agent or different active agents, and contain the same dose or different doses of the active agent.
The systems and kits may also include one or more separately packaged devices (or conventional syringes) that are to be manually loaded. If the devices are to be manually loaded prior to use, then one or more separately packaged active agents may be incorporated into the kit. 97 Similar to the preloaded device system or kit, the separately packaged active agents in the systems and kits here may be the same or different, and the dose provided by each separately packaged active agent may be the same or different.
Of course, the systems and kits may include any combination of preloaded devices, devices (or conventional syringes) for manual loading, and active agents. It should also be understood that instructions for use of the devices will also be included. In some variations, one or more separately packaged measuring components may be provided in the systems and kits for removable attachment to the devices. Topical anesthetic agents and/or antiseptic agents may also be included.
In some variations of the systems and kits, the pharmaceutical formulation is substantially non-irritating to the ocular surface. The pharmaceutical formulation is generally sterile. In one example, the pharmaceutical formulation comprises an antiseptic. In another example, the antiseptic is detergent-free. In yet another example, the antiseptic is in a single-use container. Examples of suitable antiseptic agents include, but are not limited to, iodine, iodine containing combination, povidone-iodine (Betadine®), chlorhexidine, soap, antibiotics, salts and derivatives thereof, and combinations thereof.
When the antiseptic comprises povidone-iodine (Betadine®), the concentration of povidone-iodine may range from about 1% to about 10%, from about 2.5% to about 7.5%, or from about 4% to about 6%. It may be useful for the concentration of povidone-iodine to be about 5%. The antiseptic formulation may be provided in forms that include, but are not limited to, a solution, an antiseptic-soaked swab, or a single-use reservoir suitable for ophthalmic use.
In other variations, the pharmaceutical formulation comprises an anesthetic agent that is substantially non-irritating to the ocular surface. Here the pharmaceutical formulation may contain both an antiseptic and an anesthetic agent. In other instances, the system/kit may include two separately packaged pharmaceutical formulations, where one formulation contains the antiseptic agent and the other separately packaged formulation contains the anesthetic agent. Examples of anesthetic agents include, but are not limited to, lidocaine, tetracaine. The anesthetic formulation may be provided in forms such as, but not limited to, a solution, a gel, or a anesthetic-soaked swab or spongiform material, or a single-use reservoir suitable for ophthalmic 98 use. The antiseptic agent may or may not be applied in combination with a topical anesthetic agent.
The pharmaceutical formulation may be housed in a container, where the container is integrated with the intravitreal drug injector housing, tip, drug reservoir, or any other suitable part. Alternatively, the container may be configured to detach from the intravitreal drug injector. In one example, the container is hollow reservoir, or drug-soaked sponge form material. In another example, the container is disposable and packaged for a single-use. In yet a further example, the container is sterile.
A pharmaceutical formulation may be applied on the ocular surface before placement of the device on the eye. A pharmaceutical formulation may also be applied on the ocular contact surf ace of the device tip before placement of the device on the eye. For example, an antiseptic may be applied on the ocular surface before placement of the device on the eye. In another example, an antiseptic may also be applied on the ocular contact surface of the device tip before placement of the device on the eye. In one variation, a physician may apply 5% povidone-iodine-containing pharmaceutical formulation onto the device tip prior to placing the device onto the eye surface in order to ensure sterility of the injection site.
The systems or kits for intravitreal drug delivery may comprise an integrated filter containing drug conduit, or filter-containing drug reservoir, or a filter-containing adapter for transferring and/or loading a drug from a storage container into the intravitreal injection devices described herein. In one example, the filter is a hydrophilic membrane. In another example, the filter's pore size is less than 4 microns, or less than 0.4 microns, or between 0.1 microns and 0.4 microns. In another example, the filter sterilizes a drug solution, for example, by size-exclusion filtration. Such a filter may remove bacterial pathogens. In another example, the filter removes fungal pathogens. In yet another example, the filter collectively removes bacterial, fungal and certain other pathogens.
This application further discloses the following variations 1-41, and any combination thereof:
Variation 1. An injector attachment for connection to an injection device housing comprising: a needle assembly, the needle assembly having a proximal end and a distal end; a resistance component; and an ocular contact surface.
Variation 2. The injector attachment of variation 1, wherein the resistance component comprises a slidable sleeve.
Variation 3. The injector attachment of variation 1, wherein the resistance component comprises a lever.
Variation 4. The injector attachment of variation 3, wherein the lever releasably secures a slidable sleeve.
Variation 5. The injector attachment of variation 3, wherein the lever is fixedly attached to the needle assembly.
Variation 6. The injector attachment of variation 3, wherein the lever is releasably attached to the needle assembly.
Variation 7. The injector attachment of variation 1, wherein the ocular contact surface comprises a measuring component.
Variation 8. The injector attachment of variation 1, wherein the measuring component comprises a plurality of radially extending members.
Variation 9. The injector attachment of variation 8, wherein the plurality of radially extending members are disposed 360 degrees about the circumference of the measuring component.
Variation 10. The injector attachment of variation 2, wherein the slidable sleeve is rigid.
Variation 11. The injector attachment of variation 2, wherein the slidable sleeve is nondeformable. 100
Variation 12. The injector attachment of variation 1, wherein the needle assembly further comprises a needle stabilization mechanism.
Variation 13. The injector attachment of variation 1, wherein the needle assembly further comprises one or more filters.
Variation 14. The injector attachment of variation 1, wherein the needle assembly further comprises a hydrophilic filter.
Variation 15. The injector attachment of variation 14, wherein the needle assembly further comprises a hydrophobic filter.
Variation 16. The injector attachment of variation 1, further comprising a needle deployment indicator.
Variation 17. The injector attachment of variation 16, wherein the needle deployment indicator comprises a high visibility dye.
Variation 18. A system for delivering a pharmaceutical formulation into the eye comprising: the injector attachment of variation 1; a housing; and a drug reservoir disposed within the housing.
Variation 19. The system of variation 18, wherein the housing comprises a syringe.
Variation 20. The system of variation 18, wherein the housing has a proximal end, a distal end, and a side wall, and comprises an actuation mechanism for delivering an active agent into an eye, wherein the actuation mechanism comprises a plunger.
Variation 21. The system of variation 20, wherein the actuation mechanism comprises a plunger actuation lever fixedly attached to the plunger and extending through the side wall of the housing.
Variation 22. The system of variation 21, wherein the actuation mechanism further comprises a back plunger.
Variation 23. The system of variation 18, further comprising an active agent contained within the drug reservoir.
Variation 24. The system of variation 23, wherein the active agent comprises an anti-VEGF agent selected from the group consisting of ranibizumab, bevacizumab, aflibercept, and modifications, derivatives, and analogs thereof, and combinations thereof.
Variation 25. The system of variation 24, wherein the active agent comprises ranibizumab or bevacizumab.
Variation 26. The system of variation 23, wherein the active agent comprises aflibercept, ocriplasmin, a steroid, ranibizumab, bevacizumab, a placenta-derived growth factor, a platelet-derived growth factor, or combinations thereof.
Variation 27. The system of variation 23, wherein the active agent comprises an anticomplement agent.
Variation 28. A method for injecting a pharmaceutical formulation into the eye comprising: coupling an injector attachment to a syringe having a proximal end and a distal end, the injector attachment comprising a needle assembly having a needle, and a resistance component: generating a resistive force with the resistance component; advancing the needle through the eye wall; and injecting the pharmaceutical formulation into the eye.
Variation 29. The method of variation 28, wherein the resistive force is between 0 N and about 2 N.
Variation 30. The method of variation 29, wherein the resistive force is between about 0.05 N and about 0.5 N.
Variation 31. The method of variation 28, wherein the resistance component comprises a slidable sleeve.
Variation 32. The method of variation 28, wherein the resistance component comprises a lever having a locked configuration and an unlocked configuration.
Variation 33. The method of variation 32, wherein depression of one side the lever places the lever in its unlocked configuration.
Variation 34. The method of variation 28, wherein the needle assembly further comprises a needle stabilization mechanism.
Variation 35. The method of variation 28, wherein the pharmaceutical formulation is preloaded in the syringe.
Variation 36. The method of variation 28, wherein the pharmaceutical formulation is loaded into the syringe immediately prior to its use.
Variation 37. The method of variation 30, wherein the pharmaceutical formulation comprises an active agent.
Variation 38. The method of variation 37, wherein the active agent comprises an anti-VEGF agent selected from the group consisting of ranibizumab, bevacizumab, aflibercept, and modifications, derivatives, and analogs thereof, and combinations thereof.
Variation 39. The method of variation 38, wherein the active agent comprises ranibizumab or bevacizumab.
Variation 40. The method of variation 37, wherein the active agent comprises aflibercept, ocriplasmin, a steroid, ranibizumab, bevacizumab, a placenta-derived growth factor, a platelet-derived growth factor, or combinations thereof.
Variation 41. The method of variation 37, wherein the active agent comprises an anticomplement agent.
This application also discloses the following variations 1″-50″, and any combination thereof:
Variation 1″. An injector device for drug delivery comprising: a needle assembly, the needle assembly comprising a drug conduit; a measuring component; and a priming-enabling component.
Variation 2″. The injector device of variation 1″, wherein the needle assembly is configured to removably attach to a drug reservoir.
Variation 3″. The injector device of variation 1″, wherein the needle assembly is configured to removably attach to a drug reservoir through a luer connector.
Variation 4″. The injector device of variation 3″, wherein the luer connector comprises an internal luer seal.
Variation 5″. The injector device of variation 4″, wherein the internal luer seal comprises a proximal extension of the drug conduit and is configured to open into a drug reservoir.
Variation 6″. The injector device of variation 1″, further comprising a resistance component.
Variation 7″. The injector device of variation 6″, wherein the resistance component comprises a slidable sleeve.
Variation 8″. The injector device of variation 6″, wherein the resistance component comprises a lever.
Variation 9″. The injector device of variation 8″, wherein the lever releasably secures a slidable sleeve.
Variation 10″. The injector device of variation 8″, wherein the lever is fixedly attached to the injector device.
Variation 11″. The injector device of variation 8″, wherein the lever is releasably attached to the injector device.
Variation 12″. The injector device of variation 8″, wherein the lever comprises a flexible arm connector.
Variation 13″. The injector device of variation 12″, wherein the lever has a biased position.
Variation 14″. The injector device of variation 12″, wherein the lever has a locked position.
Variation 15″. The injector device of variation 1″, wherein the measuring component comprises an ocular contact surface.
Variation 16″. The injector device of variation 1″, wherein the measuring component comprises a plurality of radially extending members.
Variation 17″. The injector device of variation 16″, wherein the plurality of radially extending members are disposed between 45 degrees and 360 degrees about the circumference of the measuring component.
Variation 18″. The injector device of variation 7″, wherein the slidable sleeve is rigid.
Variation 19″. The injector device of variation 7″, wherein the slidable sleeve is nondeformable.
Variation 20″. The injector device of variation 1″, wherein the needle assembly further comprises a needle stabilization mechanism.
Variation 21″. The injector device of variation 1″, wherein the priming-enabling component comprises a step-wise tunnel.
Variation 22″. The injector device of variation 1″, wherein the priming-enabling component comprises at least two segments, each segment having a different internal diameter.
Variation 23″. The injector device of variation 1″, wherein the needle assembly comprises one or more filters.
Variation 24″. The injector device of variation 1″, wherein the needle assembly comprises a hydrophilic filter.
Variation 25″. The injector device of variation 24″, wherein the needle assembly further comprises a hydrophobic filter.
Variation 26″. The injector device of variation 1″, further comprising a needle deployment indicator.
Variation 27″. The injector device of variation 26″, wherein the needle deployment indicator comprises a high visibility dye.
Variation 28″. The injector device of variation 23″, wherein the one or more filters comprises a sterilizing filter.
Variation 29″. The injector device of variation 28″, wherein the sterilizing filter has pore sizes between 0.1 microns and 0.4 microns.
Variation 30″. The injector device of variation 28″, wherein the sterilizing filter comprises a low-protein binding filter membrane.
Variation 31″. The injector device of variation 28″, wherein the sterilizing filter is located within the luer connector.
Variation 32″. A system for delivering a pharmaceutical formulation into the eye comprising: the injector device of variation 1″; and a drug reservoir.
Variation 33″. The system of variation 32″, wherein the drug reservoir comprises an active agent.
Variation 34″. The system of variation 33″, wherein the active agent comprises an anti-VEGF agent selected from the group consisting of ranibizumab, bevacizumab, aflibercept, and modifications, derivatives, and analogs thereof, and combinations thereof.
Variation 35″. The system of variation 33″, wherein the active agent comprises ranibizumab or bevacizumab.
Variation 36″. The system of variation 33″, wherein the active agent comprises aflibercept, ocriplasmin, a steroid, a placenta-derived growth factor, a platelet-derived growth factor, or combinations thereof. 106
Variation 37″. The system of variation 33″, wherein the active agent comprises an anticomplement agent, an anti-complement fraction agent, a complement-blocking agent, a complement-enhancing agent, a classic complement pathway inhibiting agent, an alternative complement inhibiting agent, a classic complement pathway potentiating agent, an alternative complement potentiating agent, or a combination thereof.
Variation 38″. A method for injecting a pharmaceutical formulation into the eye comprising: coupling an injector attachment to an injector device having a proximal end and a distal end, the injector attachment comprising a needle assembly having a drug conduit, a priming-enabling component, and a resistance component; priming the drug conduit using the priming-enabling component; generating a resistive force with the resistance component; advancing the drug conduit through the eye wall; and injecting the pharmaceutical formulation into the eye.
Variation 39″. The method of variation 38″, wherein the resistive force is between ON and about 2 N.
Variation 40″. The method of variation 40″, wherein the resistive force is between about 0.05 N and about 0.5 N.
Variation 41″. The method of variation 38″, wherein the resistance component comprises a slidable sleeve.
Variation 42″. The method of variation 38″, wherein the resistance component comprises a lever having a locked configuration and an unlocked configuration.
Variation 43″. The method of variation 42″, wherein depression of one side the lever places the lever in its unlocked configuration.
Variation 44″. The method of variation 38″, wherein the pharmaceutical formulation is preloaded in the syringe.
Variation 45″. The method of variation 38″, wherein the pharmaceutical formulation is loaded into the syringe immediately prior to its use.
Variation 46″. The method of variation 38″, wherein the pharmaceutical formulation comprises an active agent.
Variation 47″. The method of variation 46″, wherein the active agent comprises an anti-VEGF agent selected from the group consisting of ranibizumab, bevacizumab, aflibercept, and modifications, derivatives, and analogs thereof, and combinations thereof.
Variation 48″. The method of variation 46″, wherein the active agent comprises ranibizumab or bevacizumab.
Variation 49″. The method of variation 46″, wherein the active agent comprises aflibercept, ocriplasmin, a steroid, a placenta-derived growth factor, a platelet-derived growth factor, or combinations thereof.
Variation 50″. The method of variation 46″, wherein the active agent comprises an anti-complement agent, an anti-complement fraction agent, a complement-blocking agent, complement-enhancing agent, a classic complement pathway inhibiting agent, an alternative complement inhibiting agent, a classic complement pathway potentiating agent, an alternative complement potentiating agent, or a combination thereof.
The following examples serve to more fully describe the manner of using the above described intraocular injection devices. It is understood that this example in no way serves to limit the scope of the invention, but rather is presented for illustrative purposes.
An intraocular injection device comprising a 30-gauge needle covered by a dynamic sleeve was fixed onto an Imada tensile testing bed and moved against an Imada 10 N force gauge at a rate of 10 mm/minute. The resistance force was measured while the sleeve was pushed back to expose the needle simulating the movement of the sleeve in practice. This produced a “U”-shaped force plotted against the sleeve displacement curve, as shown in
In one instance, the resistance force at the beginning of the sleeve path equaled the force required for the 30- or 31-gauge needle to penetrate through the human sclera (e.g., between 0.2 Newton and 0.5 Newton). When a using a higher-resistance sleeve was employed, the resistance force at the beginning of the sleeve path was greater than the force required for the 30- or 31-gauge needle to penetrate through the human sclera (e.g., over 1 Newton). However, the force was low enough to be comfortable for the patient and avoid potential damage to the eye (e.g., to avoid increase in intra-ocular pressure over 60 mmHg). In the middle portion of the sleeve movement path, the force approached zero Newton.
Tests were run to compare the needle bending and recovery forces of a needle (labeled “Mini” in the graph shown in
A maximum of 30° deflection was set based on the length of the needles. Each type of needle was placed into fixture, and mill digital readouts were zeroed and the balance was tared. The test needles were moved down against the deflection fixture and the force on the scale at each test interval recorded until the maximum displacement was reached. The motion was reversed on the mill and the recovery force at each interval was recorded. Any permanent deformation of the needle was recorded.
As shown in the graph, the “Mini” needles significantly increased the bending force required to bend or deform compared to the Accu-needles and TSK needles. The 32 to 33 gauge “Mini” needles had a similar stiffness and resistance to bending as the commercially available 30 gauge needles.
Many drugs for intraocular/intravitreal use come in pre-filled syringes that are factory-packaged and sterilized with a drug inside. This is done, for example, to ensure sterility (i.e. to avoid accidental contamination during the drug transfer from a vial into a syringe by the user). In particular, the intraocular space is an immune-privileged site and any infection will cause much more severe inflammation than in other organs or tissues such as subcutaneous or intramascular sites. Also, many intraocular drugs are protein-based biopharmaceuticals that can not tolerated a preservative and a preservative may be toxic to the Intraocular neural tissues in the forest place.
Drug-prefilled syringes can have luer connectors of various designs and sizes. However, all drug-prefilled syringes are typically ISO-compliant (ISO standard: 80369) to fit a variety of injection needles also having an ISO-compliant luer taper (i.e. 6% conical fitting). Thus, syringes are typically designed to have a “male” luer connector tip having the conical fitting with the 6% taper. The length of an ISO-compliant syringe connector tip fits a needle's “female” luer taper of at least 7.5 mm in length or longer. An ISO-compliant syringe connector tip will not fit a needle's luer taper that is less than 7.5 mm.
Accordingly, embodiments of the needle hub assembly 8200 disclosed herein are configured to reduce (e.g., substantially reduce or nearly eliminate) the dead space compared to the standard ISO needle hub while also being configured to be used with any ISO-compliant syringes, such as the intravitreal drug-prefilled syringes (e.g. Lucentis®-PFS, Eylea®-PFS and Avastin®-PFS). This is unlike other conventional ocular needle products that are not compatible with an ISO-compliant syringe and will not fit any intravitreal drug-prefilled syringes because the length of the luer taper of such products is too short to be ISO 80369 compliant and will not fit an ISO 80369 syringe connector. Additionally, at least some embodiments of the needle hub assembly 8200 disclosed herein are configured to have a 6% luer taper on an inside surface 8234a of the female-type luer connector or hub 8234 to ensure a water-tight connection with any ISO-compliant syringe luer connector, including the luer-lock and lure-tip connectors.
In some embodiments, the needle hub assembly 8200 and a volume displacing protrusion 8250 formed within the needle hub assembly 8200, as will be described below, can be configured to create an air doughnut-shaped space around the volume displacing protrusion 8250 when a syringe is coupled with the needle hub assembly 8200 due to a high pressure created by the compression of the air space as the syringe is coupled with the needle hub assembly 8200. The air space can be formed radially outwardly from the volume displacing protrusion 8250, between an radially outwardly facing surface of the volume displacing protrusion 8250 and female tapered surface of the needle hub assembly 8200, and bound longitudinally by an end wall of the needle hub assembly 8200 and the syringe. This air space can get trapped when the luer syringe is inserted and forms an air-tight luer connection with the needle hub assembly 8200. Thus, in some embodiments of this configuration, when a syringe is coupled with the needle hub assembly 8200 and as fluid passes from the syringe into the needle conduit/cannula, the fluid does so without filling the air doughnut-shaped space filled with trapped air around the volume displacing protrusion 8250, or does so without appreciably filling the air doughnut-shaped space filled with trapped air around the volume displacing protrusion 8250. In some embodiments, generally speaking, the trapped air doughnut-shaped space will guide the fluid from the syringe luer toward the passageway through the needle hub assembly 8200.
Any embodiments of the needle hub assembly 8200 can have a plurality of protrusions or fins 8216 extending radially away from an outside surface of the body portion 8202. The fins 8216 can run along an axial length of the body portion 8202. A seal 8230 can be positioned at a distal end 8202b of the body portion 8202 to provide a generally fluid tight seal between the body portion 8202 and the cannula 8212. The proximal end 8202a of the body portion 8202 can have a female-type luer connector or hub 8234 that is in fluid communication with the passageway 8220 and the cannula 8212.
With reference to
Any embodiments of the needle hub assembly 8200 can be configured to minimize the dead volume or space of a device-drug reservoir system, and enhance sterility. For example and without limitation, the body portion 8202 of the needle hub assembly 8200 can have a volume displacing protrusion 8250 projecting axially away from an end wall 8252 of the body portion 8202 toward the proximal end 8202a of the body portion 8202. For reference, an end of the volume displacing protrusion 8250 closer to the proximal end 8202a of the body portion 8202 is referred to herein as the proximal end 8250a of the volume displacing protrusion 8250 and the opposite end of the volume displacing protrusion 8250 that is closer to the distal end 8202b of the body portion 8202 is referred to herein as the distal end 8250b of the volume displacing protrusion 8250.
The passageway 8220 can extend through the volume displacing protrusion 8250 so that the passageway 8220 and the lumen of the cannula 8212 are in communication with the cavity 8207, thereby allowing a medicament or other fluid within an injection device coupled with the needle hub assembly 8200 to be advanced through the cavity 8207, the passageway 8220, and through the cannula 8212 into the desired injection site as the plunger 8221 is depressed.
In any embodiments, the volume displacing protrusion 8250 can have a sloped outer surface 8270 which can have the shape of a truncated cone. The proximal end 8250a of the volume displacing protrusion 8250 can have a diameter (represented by D1—shown in
Additionally, in any embodiments, the volume displacing protrusion 8250 can have a diameter (represented by D3—shown in
In any embodiments, the end wall 8252 can have a diameter (represented by D4—shown in
In any embodiments, a width or thickness of a wall of the volume displacing protrusion 8250 (represented by D5—shown in
Additionally, with reference to
In any embodiments, the length D7 of the volume displacing protrusion 8250 can be 0.5 mm or approximately 0.5 mm, or less than or equal to 0.5 mm or approximately 0.5 mm, or from 0.1 mm or approximately 0.1 mm to 1.5 mm or approximately 1.5 mm, or from 0.3 mm or approximately 0.3 mm to 1 mm or approximately 1 mm, or from 0.3 mm or approximately 0.3 mm to 0.7 mm or approximately 0.7 mm, or from 0.4 mm or approximately 0.4 mm to 0.6 mm or approximately 0.6 mm, or of any value, approximate value, or range of values in any of the foregoing ranges. In any embodiments, the length D7 of the volume displacing protrusion 8250 can be 25% or approximately 25% of a length D8 (shown in
In any embodiments disclosed herein, the syringe cap can have any of the components, features, or other details of any other luer taper device embodiments disclosed herein, including without limitation any of the other embodiments of the needle hub assembly 8200 described herein, in any combination with any of the components, features, or details of the syringe cap device 8400 shown in
The first end 8402 (also referred to herein as the proximal end) of the syringe cap 8400 can have tapered opening that is ISO-compliant (ISO standard: 80369) to fit/receive a variety of injection needles also having an ISO-compliant luer taper (i.e. 6% conical fitting). In some embodiments, the second end 8440 can have a female luer taper of at least 7.5 mm in length or longer. Accordingly, any embodiments of the syringe cap 8400 or other luer taper devices disclosed herein can be configured to receive a “male” luer connector tip having the conical fitting with the 6% taper.
In any embodiments disclosed herein, the syringe cap 8400 can include a body portion 8401 having an opening 8406 in the first end 8402 in communication with a cavity or internal space 8407 within a proximal portion of the body portion 8401. The body portion 8401 can also have one or more threads 8408 at a proximal end 8402a of the body portion 8401.
Many drugs for intraocular/intravitreal use come in pre-filled syringes that are factory-packaged and sterilized with a drug inside. This is done, for example, to ensure sterility (i.e. to avoid accidental contamination during the drug transfer from a vial into a syringe by the user). In particular, the intraocular space is an immune-privileged site and any infection will cause much more severe inflammation than in other organs or tissues such as subcutaneous or intramascular sites. Also, many intraocular drugs are protein-based biopharmaceuticals that can not tolerated a preservative and a preservative may be toxic to the Intraocular neural tissues in the forest place.
Any embodiments of the syringe cap 8400 disclosed herein can be configured to reduce (e.g., substantially reduce or nearly eliminate) the dead space compared to the standard ISO caps or other luer taper devices while also being configured to be used with any ISO-compliant syringes, such as the intravitreal drug-prefilled syringes (e.g. Lucentis®-PFS, Eylea®-PFS and Avastin®-PFS). This is unlike other conventional cap products that are not compatible with an ISO-compliant syringe and will not fit any intravitreal drug-prefilled syringes because the length of the luer taper of such products is too short to be ISO 80369 compliant and will not fit an ISO 80369 syringe connector. Additionally, at least some embodiments of the syringe cap 8400 disclosed herein are configured to have a 6% luer taper on an inside surface 8434 of the female-type luer connector or hub to ensure a water-tight connection with any ISO-compliant syringe luer connector, including the luer-lock and lure-tip connectors.
In some embodiments, the syringe cap 8400 and a volume displacing protrusion 8450 (also referred to herein as a low dead space protrusion protrusion) formed within the syringe cap 8400, as will be described below, can be configured to create an air doughnut-shaped space around the volume displacing protrusion 8450 when a syringe is coupled with the syringe cap 8400 due to a high pressure created by the compression of the air space as the syringe is coupled with the syringe cap 8400. The air space can be formed radially outwardly from the volume displacing protrusion 8450, between a radially outwardly facing surface of the volume displacing protrusion 8450 and female tapered surface of the syringe cap 8400, and bound longitudinally by an end wall 8460 of the syringe cap 8400, and the syringe. This air space can get trapped when the luer syringe is inserted and forms an air-tight luer connection with the syringe cap 8400.
In some embodiments, the volume displacing protrusion 8450 can be configured to prevent air from entering an end of the syringe tip. For example and without limitation, some embodiments of the syringe cap 8400 can be configured such that the volume displacing protrusion 8450 creates a seal with an end of the syringe tip before the inside wall 8434 of the opening 8406 seals against an outside surface of the syringe tip (e.g., without limitation, to create a substantially airtight seal). This can permit air inside the internal space 8407 to escape the internal space 8407 while the syringe tip is being advanced into the opening 8406 and also result in the end of the syringe tip being sealed by the volume displacing protrusion 8450 before there is a buildup of pressure within the internal space 8407 by the advancement of the syringe tip into the opening 8406. By sealing the end of the syringe tip before there is a buildup of pressure in the internal space 8407, this can also inhibit (e.g., without limitation, prevent) air intrusion into the syringe tip.
Any embodiments of the syringe cap 8400 can have a plurality of protrusions or fins 8416 extending radially away from an outside surface of the body portion 8401. The fins 8416 can run along a portion of an axial length of the body portion 8401. The second end 8404 can be configured to provide a gripping and/or grasping portion for a user of the device.
With reference to
In some embodiments, the body portion 8401 of the syringe cap 8400 can have a recess 8412 formed in the second end 8404 of the syringe cap 8400. The recess 8412 can extend in a longitudinal axial direction toward the first end 8402 of the syringe cap 8400 to any desired depth. In some embodiments, the recess 8412 can extend into the body portion 8401 of the syringe cap 8400 by a depth of 4.2 mm, or approximately 4.2 mm, or from 3 mm, approximately 3 mm, or less than 3 mm to 6 mm, approximately 6 mm, or more than 6 mm, or from 4 mm, approximately 4 mm, or less than 4 mm to 5 mm, approximately 5 mm, or more than 5 mm, or of any value or range of values within any of the foregoing ranges.
An end wall 8452 can extend from a bottom surface 8412a of the recess 8412 toward the first end 8402 of the syringe cap 8400. In some embodiments, the end wall 8452 can have any desired or suitable thickness. For example and without limitation, the end wall 8452 can have a thickness represented by dimension D9 in
Additionally, in some embodiments, the end wall 8452 can be generally flat and can have a flexible insert adjacent to the end wall 8452 made of a more flexible material such as silicone or another flexible or elastic material. The flexible insert can have a volume displacing protrusion formed thereon having any of the features, shapes, and/or dimensions of any of the volume displacing protrusion embodiments disclosed herein. In some embodiments, the flexible insert can be configured to be snugly inserted into the internal space 8407 adjacent to the end wall 8452. The flexible insert can, in some embodiments, have a generally disc-like shape (such as, for example and without limitation, like a diaphragm) with the volume displacing protrusion extending from one main surface of the volume displacing protrusion.
In some embodiments, the body portion 8401 can be formed in two parts or halves and be configured to be coupled or joined together. The interface or parting line between the two parts can be parallel to the end wall surface 8452 and be between the end wall surface 8452 and the bottom surface 8412a of the recess 8412. A flexible insert can be positioned between the two halves or parts, the flexible insert having a volume displacing protrusion formed thereon having any of the features, shapes, and/or dimensions of any of the volume displacing protrusion embodiments disclosed herein.
As mentioned, any embodiments of the syringe cap 8400 can be configured to minimize the dead volume or space of a device-drug reservoir system, and enhance sterility. For example and without limitation, the body portion 8401 of the syringe cap 8400 can have a volume displacing protrusion 8450 projecting axially away from the end wall 8452 of the body portion 8401 toward the proximal end 8401a of the body portion 8401. For reference, an end of the volume displacing protrusion 8450 closer to the proximal end 8401a of the body portion 8401 is referred to herein as the proximal end 8450a of the volume displacing protrusion 8450 and the opposite end of the volume displacing protrusion 8450 that is closer to the distal end 8401b of the body portion 8401 is referred to herein as the distal end 8450b of the volume displacing protrusion 8450.
In any embodiments, the volume displacing protrusion 8450 can have a curved outer surface 8470. In some embodiments, the outer surface 8470 can be spherical. In some embodiments, the outer surface 8470 can have the shape of a truncated cone. In any embodiments disclosed herein, the volume displacing protrusion can be configured to never extend into an inside portion of an end of the syringe. In some embodiments, the volume displacing protrusion can be configured to never substantially extend into an inside portion of an end of the syringe but, rather, to flex and compress or move when the syringe tip contacts the volume displacing protrusion (e.g., can be configured to never enter the inside portion of the syringe to any extent that would impede or block a movement of the plunger inside the syringe). In any embodiments disclosed herein, the syringe cap can be configured to be used with any embodiments of a low dead space syringe known or disclosed herein, including without limitation, embodiments of the low dead space syringe wherein the plunger extends all the way to the distal end of the syringe tip, and embodiments of the low dead space syringe wherein the plunger has a flat distal end.
In some embodiments, where the volume displacing protrusion 8450 has a truncated conical shape, the proximal end 8450a of the volume displacing protrusion 8450 can have a diameter (not shown) that is smaller than a diameter of the volume displacing protrusion 8450 at the distal end 8450b of the volume displacing protrusion 8450. In some embodiments, the diameter of the proximal end 8450a of the volume displacing protrusion 8450 can be 2 mm or approximately 2 mm, or can be from 1 mm or approximately 1 mm to 2.5 mm or approximately 2.5 mm, or from 1.5 mm or approximately 1.5 mm to 2 mm or approximately 2 mm, or of any value, approximate value, or range of values in any of the foregoing ranges. Consequently, the distal end 8450b of the volume displacing protrusion 8450 can have a diameter (represented by D2—shown in
In any embodiments, the end wall 8452 can have a diameter (represented by D4—shown in
In some embodiments, the diameter D2 of the distal end 8450b of the volume displacing protrusion 8450 can be 64% or approximately 64% of the diameter D4 of the end wall 8452, or from 50% or approximately 50% to 80%, approximately 80%, or more than 80% of the diameter D4 of the end wall 8452, or from 50% or approximately 50% to 70%, approximately 70%, or more than 70% of the diameter D4 of the end wall 8452, or of any value, approximate value, or range of values in any of the foregoing ranges.
Additionally, with reference to
In some embodiments, the length (also referred to herein as a height) D7 of the volume displacing protrusion 8450 can be shorter than a distance between the end wall 8452 and a distal end of a syringe that is fully engaged with the syringe cap 8400 but be long enough to be within 0.5 mm or approximately 0.5 mm, or to be within 0.25 mm or approximately 0.25 mm of a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use.
In some embodiments, the volume displacing protrusion 8450 can be sized and configured such that a distance in a longitudinal axial direction between the proximal end 8450a of the volume displacing protrusion 8450 and a distal end of a syringe that is fully engaged with the syringe cap 8400 is less than 10% or less than approximately 10% of a distance in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use, or less than 5% or less than approximately 5% of a length in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use, or from 5%, approximately 5%, or less than 5% to 20% or approximately 20% of a length in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use.
In some embodiments, the volume displacing protrusion 8450 can be sized and configured such that the height D7 in a longitudinal axial direction between the end wall 8452 and the proximal end 8450a of the volume displacing protrusion 8450 (when the volume displacing protrusion 8450 is in a relaxed state, before the syringe tip makes contact with the volume displacing protrusion 8450) is at least 10%, greater than 10%, greater than approximately 10%, or is 10% or less than 10% of a distance in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use. This can ensure that the distal end of the syringe tip contact and presses against the volume displacing protrusion 8450 when the syringe tip is advanced into the internal space 8407. Additionally, as described elsewhere in this disclosure, some embodiments of the volume displacing protrusion 8450 and/or the end wall 8452 can be deformable such that, when the syringe tip is advanced into the internal space 8407 and into contact with the volume displacing protrusion 8450, the volume displacing protrusion 8450 and/or the end wall 8452 deforms or compresses in an axial direction toward the second end 8404 of the syringe cap 8400 to allow the syringe tip to fully engage with the syringe cap 8400 (for example and without limitation, so that a seal is created between the syringe tip and the tapered luer of the syringe cap 8400.
In some embodiments, the volume displacing protrusion 8450 can be sized and configured such that the height D7 in a longitudinal axial direction between the end wall 8452 and the proximal end 8450a of the volume displacing protrusion 8450 (when the volume displacing protrusion 8450 is in a relaxed state, before the syringe tip makes contact with the volume displacing protrusion 8450) is at least 15%, greater than 15%, or greater than approximately 15% of a distance in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use. In some embodiments, the volume displacing protrusion 8450 can be sized and configured such that the height D7 in a longitudinal axial direction between the end wall 8452 and the proximal end 8450a of the volume displacing protrusion 8450 (when the volume displacing protrusion 8450 is in a relaxed state, before the syringe tip makes contact with the volume displacing protrusion 8450) is at least 20%, greater than 20%, greater than approximately 20%, or is 20% or less than 20% of a distance in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use. In some embodiments, the volume displacing protrusion 8450 can be sized and configured such that the height D7 in a longitudinal axial direction between the end wall 8452 and the proximal end 8450a of the volume displacing protrusion 8450 (when the volume displacing protrusion 8450 is in a relaxed state, before the syringe tip makes contact with the volume displacing protrusion 8450) is from 10% or approximately 10% to 20% or approximately 10% of a distance in a longitudinal axial direction between the end wall 8452 of the syringe cap 8400 and a distal end of a syringe that is fully engaged with the syringe cap 8400 during normal operational use.
In any embodiments, the height D7 of the volume displacing protrusion 8450 can be 0.5 mm or approximately 0.5 mm, or less than or equal to 0.5 mm or approximately 0.5 mm, or from 0.1 mm or approximately 0.1 mm to 1.5 mm or approximately 1.5 mm, or from 0.3 mm or approximately 0.3 mm to 1 mm or approximately 1 mm, or from 0.3 mm or approximately 0.3 mm to 0.7 mm or approximately 0.7 mm, or from 0.4 mm or approximately 0.4 mm to 0.6 mm or approximately 0.6 mm, or of any value, approximate value, or range of values in any of the foregoing ranges. In any embodiments, the height D7 of the volume displacing protrusion 8450 can be 25% or approximately 25% of a length D8 (shown in
In some embodiments, the height D7 can be 10%, approximately 10%, or less than 10%, or 8%, approximately 8%, or less than 8%, or 12%, approximately 12%, or less than 12% of the thickness D9 of the end wall 8452, or from 8%, approximately 8%, or less than 8% to 12%, approximately 12%, or less than 12% of the thickness D9 of the end wall 8452, or from 5%, approximately 5%, or less than 5% to 15%, approximately 15%, or less than 15% of the thickness D9 of the end wall 8452, or of any value, approximate value, or range of values in any of the foregoing ranges. Additionally, in any embodiments disclosed herein, the height D7 of the volume displacing protrusion 8450 can be sufficient to make contact with an end of a syringe tip and to create a seal with the end of the syringe tip before the outside surface of the syringe tip makes a seal with the luer taper. In some embodiments, the volume displacing protrusion 8450 can have a spherical outside surface having a radius R (shown in
In some embodiments, the syringe cap 8400 can be configured such that the end wall and/or the volume displacing protrusion 8450 can flex or deform (e.g., elastically) when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. In some embodiments, the syringe cap 8400 can be configured such that the end wall and/or the volume displacing protrusion 8450 will deflect in a longitudinal axial direction toward the second end 8404 of the syringe cap 8400 when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. Some embodiments of the syringe cap 8400 can be configured such that the end wall and/or the volume displacing protrusion 8450 can flex or deform (e.g., elastically) a small amount when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. For example and without limitation, some embodiments of the syringe cap 8400 can be configured such that the end wall and/or the volume displacing protrusion 8450 can flex or deform (e.g., elastically) toward the second end 8404 of the syringe cap 8400 by a distance of 5%, approximately 5%, or up to 5% of the height D7 of the volume displacing protrusion 8450, or by a distance of 10%, approximately 10%, or more than 10% of the height D7 of the volume displacing protrusion 8450, or by a distance of 15%, approximately 15%, or more than 15% of the height D7 of the volume displacing protrusion 8450, or from 5%, approximately 5%, or up to 5% to 20%, approximately 20%, or more than 20% of the height D7 of the volume displacing protrusion 8450, when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. Some embodiments of the syringe cap 8400 can be configured such that the end wall and/or the volume displacing protrusion 8450 can flex or deform (e.g., elastically) toward the second end 8404 of the syringe cap 8400 by a distance of 15%, approximately 15%, or up to 15% of the height D7 of the volume displacing protrusion 8450, or by a distance of 25%, approximately 25%, or more than 25% of the height D7 of the volume displacing protrusion 8450, or by a distance of 50%, approximately 50%, or more than 50% of the height D7 of the volume displacing protrusion 8450, or from 10%, approximately 10%, or up to 10% to 50%, approximately 50%, or more than 50% of the height D7 of the volume displacing protrusion 8450, when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. In any embodiments disclosed herein, the syringe cap 8400 or luer device can have a flexible septum or diaphragm or other flexible element having the volume displacing protrusion 8450 on the flexible septum or diaphragm, or where the end wall itself is flexible, the end wall and/or the volume displacing protrusion 8450 can flex or deform (e.g., elastically) toward the second end 8404 of the syringe cap 8400 by a distance of 50%, approximately 50%, or up to 50% of the height D7 of the volume displacing protrusion 8450, or by a distance of 75%, approximately 75%, or more than 75% of the height D7 of the volume displacing protrusion 8450, or by a distance of 100%, approximately 100%, or more than 100% of the height D7 of the volume displacing protrusion 8450, or from 50%, approximately 50%, or up to 50% to 100%, approximately 100%, or more than 100% of the height D7 of the volume displacing protrusion 8450, when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. Some embodiments of the syringe cap 8400 can be configured such that the end wall and/or the volume displacing protrusion 8450 does not flex or deform significantly (for example, less than 5%, or less than 2% of the height D7 of the volume displacing protrusion 8450) when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400.
Additionally, in any embodiments of the syringe cap 8400 disclosed herein, a depression 8465 can be formed in bottom surface 8412a of the recess 8412. Some embodiments of the bottom surface 8412a of the recess 8412 can be generally flat and continuous, i.e., without a recess or depression 8465 formed therein. When present, the depression 8465 can be configured to increase a flexibility of the end wall 8452 so that the end wall and/or the volume displacing protrusion 8450 can deflect in a longitudinal axial direction toward the second end 8404 of the syringe cap 8400 when a syringe is advanced into contact with the volume displacing protrusion 8450 during normal operational use of the syringe cap 8400. In some embodiments, the depression 8465 can have a width (represented by D10 in
In any embodiments disclosed herein, the syringe cap 8400 can be made from a pliable material, such as a plastic or a rubber material. For example and without limitation, some embodiments of the syringe cap 8400 can be made from polyethylene, polypropylene, a thermoplastic elastomer (TPE), rubber, silicone, or any other suitable material. In any embodiments disclosed herein, the syringe cap 8400 can be made from an elastic, soft, or flexible material. In some embodiments, the material can be suitable for medical applications and be suitable for sterilizations, including for multiple sterilizations.
Various other modifications, adaptations, and alternative designs are of course possible in light of the above teachings. Therefore, it should be understood at this time that within the scope of the appended claims the invention may be practiced otherwise than as specifically described herein. It is contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments disclosed above may be made and still fall within one or more of the inventions. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with an embodiment can be used in all other embodiments set forth herein. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above.
Moreover, while the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “applying pressure on a plunger to create an audible and/or tactile click feedback” includes “instructing the applying of pressure on a plunger to create an audible and/or tactile click feedback.”
While certain arrangements of the inventions have been described, these arrangements have been presented by way of example only, and are not intended to limit the scope of the disclosure. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the systems and methods described herein may be made without departing from the spirit of the disclosure. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the disclosure. Accordingly, the scope of the present inventions is defined only by reference to the appended claims.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, arrangement, or example are to be understood to be applicable to any other aspect, arrangement or example described in this section or elsewhere in this specification unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing arrangements. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Furthermore, certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable subcombination. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can, in some cases, be excised from the combination, and the combination may be claimed as a subcombination or variation of a subcombination.
Moreover, while operations may be depicted in the drawings or described in the specification in a particular order, such operations need not be performed in the particular order shown or in sequential order, or that all operations be performed, to achieve desirable results. Other operations that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the described operations. Further, the operations may be rearranged or reordered in other implementations. Those skilled in the art will appreciate that in some arrangements, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the arrangement, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific arrangements disclosed above may be combined in different ways to form additional arrangements, all of which fall within the scope of the present disclosure. Also, the separation of various system components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. Not necessarily all such advantages may be achieved in accordance with any particular arrangement. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain arrangements include, while other arrangements do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more arrangements or that one or more arrangements necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular arrangement.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain arrangements require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic equal to or close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of the stated amount. As another example, in certain arrangements, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15°, 10°, 5°, 3°, 1 degree, or 0.1 degree. The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof, and any specific values within those ranges. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers and values used herein preceded by a term such as “about” or “approximately” include the recited numbers. For example, “approximately 7 mm” includes “7 mm” and numbers and ranges preceded by a term such as “about” or “approximately” should be interpreted as disclosing numbers and ranges with or without such a term in front of the number or value such that this application supports claiming the numbers, values and ranges disclosed in the specification and/or claims with or without the term such as “about” or “approximately” before such numbers, values or ranges such, for example, that “approximately two times to approximately five times” also includes the disclosure of the range of “two times to five times.” The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred arrangements in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.
This application is a continuation-in-part of U.S. application Ser. No. 17/993,309 filed on Nov. 23, 2022, which is a continuation of U.S. application Ser. No. 15/917,540 filed on Mar. 9, 2018 (now U.S. Pat. No. 11,554,041), which is a continuation of U.S. application Ser. No. 15/445,882 filed on Feb. 28, 2017 (now U.S. Pat. No. 9,913,750), which is a continuation of U.S. application Ser. No. 14/839,795 filed on Aug. 28, 2015 (now U.S. Pat. No. 9,603,739), which is a continuation of U.S. application Ser. No. 14/047,476 filed on Oct. 7, 2013 (now U.S. Pat. No. 9,504,603), which is a continuation-in-part of U.S. application Ser. No. 13/841,144 filed Mar. 15, 2013 (now U.S. Pat. No. 9,421,129), which claims priority to U.S. Provisional Application Ser. No. 61/619,308 filed Apr. 2, 2012, and U.S. Provisional Application Ser. No. 61/668,588 filed Jul. 6, 2012. This application also claims priority to U.S. Provisional Application Ser. No. 63/514,304 filed Jul. 18, 2023, the disclosures of which are hereby incorporated by reference in their entireties as if fully set forth herein.
| Number | Date | Country | |
|---|---|---|---|
| 61619308 | Apr 2012 | US | |
| 61668588 | Jul 2012 | US | |
| 63514304 | Jul 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15917540 | Mar 2018 | US |
| Child | 17993309 | US | |
| Parent | 15445882 | Feb 2017 | US |
| Child | 15917540 | US | |
| Parent | 14839795 | Aug 2015 | US |
| Child | 15445882 | US | |
| Parent | 14047476 | Oct 2013 | US |
| Child | 14839795 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17993309 | Nov 2022 | US |
| Child | 18408461 | US | |
| Parent | 13841144 | Mar 2013 | US |
| Child | 14047476 | US |
